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ABSTRACT
Background/Objectives: Children born to mothers with opioid use disorder often show
withdrawal effects characterized by increased stress, hyperirritability, tremors, tachycardia,
sleep deprivation, and gastrointestinal discomfort, commonly known as “neonatal opioid
withdrawal syndrome” (NOWS). Studies have shown that the effect of NOWS can lead to
several health-related disorders later in life leading to increased health care utilization.
However, detailed study of post-discharge health care utilization, specifically focusing on
encounters with the health care system is currently lacking in the literature. Our objective
was to evaluate health care utilization in infants who were diagnosed with NOWS during
a one-year follow-up period after their discharge from the hospital. Secondly, we wanted
to assess the relationship between NOWS related severity measures and post-discharge
health care utilization during a one-year follow-up period.
Methods: Health Facts® data, collected from over 800 contributing CERNER hospitals
across the United States, was used to identify infants who were diagnosed with NOWS.
Health care utilization during a follow-up period of 365 days after the index period
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(discharge date) was evaluated. As comparators, two groups were utilized: late preterm
(gestational age: 33 weeks up to 36 6/7 weeks) and uncomplicated birth infants. Outcomes
measured were rehospitalization, emergency department visits and outpatient visits. We
used logistic regression model to assess the impact of NOWS on health care utilization
after discharge. Poisson and Zero-inflated Poisson regression were used to quantify the
incidence rates of the health care utilization event. Finally, Cox proportional-hazards
regression was used to estimate time to first event related to health care utilization after
discharge from the hospital.
Results: We identified our study cohort as infants who had birth related discharges between
the period of January 1, 2011, and October 31, 2016 which included 3,526 infants with
NOWS, 24,474 infants who had late preterm birth, and 88,452 infants who had
uncomplicated births (representing a 25% sample of the births recorded). Mirroring the
opioid epidemic in the U.S. there was an increasing trend in the incidence rate of NOWS.
Infants with NOWS had significantly longer length of stay (14.9 days vs. 2.1 days,
p<0.001), and higher cost (Median: $24,944 vs. $3,129, p<0.001) compared to
uncomplicated birth group. Infants diagnosed with NOWS had significantly higher odds of
one-year rehospitalization (Adjusted odds ratio: 1.7, 95% C.I.: 1.3-2.2) and 30-day
rehospitalization (Adjusted odds ratio: 1.9, 95% C.I.: 1.3-2.6) compared to uncomplicated
birth infants. There was no statistical difference in the risk of emergency department visits
in the NOWS group compared to uncomplicated birth group after adjustment for
confounders. Infants in the NOWS group had higher odds of any 30-day composite visit
(emergency department visit or rehospitalization) compared to the uncomplicated birth
group (Adjusted odds ratio: 1.4, 95% C.I.: 1.2-1.6). The results from logistic regression
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models closely aligned with the findings from the Poisson, Zero-inflated Poisson, and Cox
proportional-hazards regression models. Infants with NOWS had similar rates of postdischarge healthcare utilization when compared to late preterm infants. In examining the
impact of NOWS severity measures on post-discharge health care utilization, we found
that some of the measures, such as pharmacological management of NOWS, length of stay,
receiving medications (e.g., benzodiazepines), and presence of respiratory conditions were
associated with higher probability of post-discharge health care utilization. While the
results from logistic regression models were inconsistent, results from principal component
analysis, which combined NOWS severity measures, showed that NOWS severity was
associated with post-discharge health care utilization.
Conclusions/Implications: Our study shows that the higher rates of health care utilization
of infants who were diagnosed with NOWS is not just limited to a period of hospitalization
for NOWS treatment but can also manifest for an extended period of time post-discharge.
Hospital readmissions and emergency department visits could lead to additional physical,
mental, and financial stress to the families of the affected infants. Furthermore, they signal
presence of an underlying medical condition that could lead to poor health and even infant
mortality. The findings of our study suggest that closer follow-up and management of
infants may be necessary. Additional support to the infant-maternal dyad may help in
improving health outcomes in these infants in the early years of their lives.
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CHAPTER 1: INTRODUCTION
1.1 Opioid use in pregnancy
Opioid use among women of reproductive age has been increasing steadily over the
past decade. At least a third of women between the ages of 15-44 years filled a prescription
for opioid as an outpatient each year between the years 2008 to 2012.1 Reflecting the
increase in the use of opioids among women of reproductive age, there has been a
noteworthy increase in opioid use during pregnancy. A report on Medicaid patients stated
that approximately 21.6% of pregnant women on Medicaid had filled a prescription for
opioids.2 The rates had gradually increased from 18.5% in 2000 to 22.8% in 2007.2 In
addition, 2.5% of the pregnant women on Medicaid had received prescription opioids for
more than 30 days signifying prolonged exposure to opioids.2 In commercially insured
pregnant women, the prevalence of opioid prescription varied from 6 to 26%.3 Studies
conclude that the rate of prescription opioid use in pregnant women has grown two-folds
in the last two decades.1-5
Increase in prescription opioid use has led to a surge in the non-medical use of
opioids as well as the use of illicit opioids (e.g., heroin) during pregnancy. As the supply
of prescription opioids is limited by physicians or as cost becomes a barrier, there is
invariably a shift towards cheaper illicit opioids which is facilitated by the ease of
availability.6 The increasing trend in licit and illicit opioid use in women of reproductive
age has resulted in a sharp increase in pregnant women who required treatment for opioid
abuse. In 1992, approximately 2% of the pregnant women admitted to a substance abuse
treatment program reported that opioid was the primary substance that they abused; the
1

proportion increased to approximately 19% in 2012.7 Over two-thirds of pregnant women
in a substance abuse treatment programs have a history of heroin use suggesting that origins
of substance use disorder stem from both illicit drugs and misuse of prescription
medications.8
1.2 Opioid use disorder in pregnancy
Opioids are any substances, natural or synthetic, which bind to the opioid receptors
and modulate the pain, and other neurosensory activities of the body.9 Prolonged use of
opioids causes an imbalance in the activity of these receptors resulting in the patients to
show the symptoms of opioid use disorder (OUD). OUD is characterized by craving,
tolerance, impulsive, and continued use of opioids regardless of the adverse effects on the
individual’s health.10 As with any disorder, OUD is considered a manageable condition
that can be treated through medical and behavioral therapy. Medication Assisted Treatment
(MAT) has been the cornerstone of treatment of OUD.11 The treatment focuses on the
substitution of illicit opioids by long-acting opioids that addresses the cravings of the
individual while preventing adverse events that are associated with illicit opioids. OUD is
treated with a drug that is either a full agonist (methadone) or a partial agonist
(buprenorphine) of the opioid receptors. Administration of MAT is ideally a part of a broad
treatment program that consists of addiction counseling, family therapy, and other social
services.12,13 It is important to note that there are only a limited number of providers in the
United States that provide both substance abuse treatment and prenatal care.14,15 While
measures are being undertaken to expand the access to these services in pregnant women
with OUD, substantial gaps exist in the perinatal and postnatal care of pregnant women
with OUD.16
2

1.3 Outcomes associated with opioid use in pregnancy
1.3.1 Neonatal outcomes
Use of illicit opioids, such as heroin, is associated with increased risk of prematurity
and intrauterine growth restriction.17,18 Compared to infants born to a mother on
methadone, infants born to mother who used heroin had lower weight, length, and head
circumference at birth.19,20 Additionally, evidence suggests that opioid use may be
associated with birth defects such as congenital heart defects, neural tube defects, and
clubfoot. However, these conclusions have been derived primarily from case-control
studies and not all studies were adjusted for prenatal environment.21 A study that analyzed
the outcomes of prescription opioid used during pregnancy showed greater odds of preterm
labor, premature delivery, fetal growth disorders, longer hospital stays, and maternal-fetal
mortality compared to no opioid use.22 Adverse neonatal outcomes associated with in-utero
exposure to opioids can substantially increase the risk of adverse health outcomes later in
the life of the infant.
1.3.2 Neonatal opioid withdrawal syndrome
More than half of the infants born to pregnant women with OUD develop
withdrawal symptoms such as increased stress, hyperirritability, tremors, tachycardia,
sleep deprivation, and gastrointestinal discomfort, which are collectively known as
neonatal opioid withdrawal syndrome (NOWS), formerly known as neonatal abstinence
syndrome (NAS).23,24 Reflecting the steady growth in OUD during pregnancy, there has
been a substantial increase in the incidence of NOWS and other opioid-related adverse
events.21 These infants require considerable amount of pharmacologic and non-
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pharmacologic treatments, and have prolonged hospital stays after birth leading to a
considerable economic burden to the health system.25
1.4 Health care utilization in infants with NOWS
Infants born with NOWS have prolonged hospital stay and higher health care
utilization during their hospitalization.25 Strategies, such as standardizing treatment
protocols, management in outpatient settings, or use of adjunctive therapies for treatment
of NOWS, have been evaluated to minimize the cost related to management of NOWS.2629

These studies aim to decrease the exposure to opioids during withdrawal and/or to

decrease the length of stay (LOS) in the hospital and effectively reducing the cost of
managing NOWS.30 However, there is very little consensus on the approaches to treatment
in NOWS31-33 and its impact on long-term health-care utilization. Furthermore, most
published research on NOWS is concentrated on the management of withdrawal effects
and reducing LOS. Studies that evaluate long-term effects in-utero exposure to opioids and
resultant health care utilization have been overlooked. A report evaluating health care
utilization in a cohort of 499 infants who were diagnosed with NOWS during the first year
of their life reported that 15% of the cohort required hospital readmissions and 22% of
those who were readmitted required further readmissions.34 Another study showed that
children who had been diagnosed with NOWS/NAS had increased readmission rates in the
first five years of life compared to controls.35 Infants with NOWS who are discharged after
less than 7 days of hospital stay have higher rates of hospital readmission compared to
those who were discharged after 7 days.36 Additionally, infants could also be prescribed
barbiturates to alleviate their NOWS symptoms.37 However, the safety and efficacy of
prolonged exposure to barbiturates in the newborn period is not well characterized.38-40
4

While the treatment with opioids (with morphine or methadone) or treatment with
phenobarbital is effective for the management of the symptom of NOWS, the infants
require a gradual decrease in the medication dosing until it can be safely discontinued,
resulting in longer hospital stays compared to infants who did not receive these
medications. The management of NOWS with these medications early in the life of the
infant, combined with the effect of in-utero exposure to opioids may lead to poor health
outcomes later in life. The rising concerns regarding NOWS in relation to the opioid
epidemic in the U.S. warrants a critical evaluation of its long-term consequences.
Understanding the various treatment modalities in response to the severity of NOWS and
the outcomes associated with these treatments can significantly contribute to improving the
health outcomes and lowering the economic burden of the condition.
1.5 Study objectives
The overall goal of this study was to characterize and quantify post-discharge health
care utilization in infants with NOWS compared to controls during a one-year follow-up
period. The study utilized two control groups: a primary control group that included infants
with uncomplicated births and a second control group that included late preterm births
(gestational age: 33 weeks to 36 6/7 weeks). Secondary controls served as close
comparators to the NOWS group as the condition overall is considered self-limiting,
however, late preterm infants are susceptible to poor health and increased health care
utilization during early life.41,42 Post-discharge health care utilization was characterized by
hospital readmissions, emergency department visits, and outpatient visits during a period
of 365 days after discharge. In addition, this study evaluated the association between the
severity of NOWS and how it affected health care utilization post-discharge. This study
5

utilized the Cerner Health Facts® (HF) database which includes de-identified electronic
health records (EHR) from 872 participating CERNER hospital and clinics in the U.S.
(years 2011-2017). We hypothesized that infants who were diagnosed with NOWS at
birth would have higher post-discharge health care utilization compared to infants
without NOWS. Additionally, we hypothesized that pharmacological management of
NOWS, use of adjunctive therapy (indices of NOWS severity) along with LOS and
other medical conditions related to NOWS would be associated with overall increased
post-discharge health care utilization. To test these hypotheses we proposed the
following Specific Aims:
1.6 Specific Aims
Aim 1: To compare and characterize post-discharge health care utilization of infants
born with NOWS compared to controls (uncomplicated births and late preterm
births) during a one-year follow-up period.
Hypothesis 1: Infants born with NOWS will show significantly higher post-discharge
health care utilization compared to both control groups owing to the exposure to opioids
in utero, and during the management of NOWS.
Aim 1 will be evaluated through the following sub-aims:
1.A) To compare the hospital readmissions in infants born with NOWS to controls.
1.B) To compare the emergency department visits in infants born with NOWS to
controls.
1.C) To compare the outpatient visits in infants born with NOWS to controls.
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Aim 2: To evaluate the relationship between NOWS severity measures
(pharmacologic management of NOWS, use of adjunctive therapy, concurrently
diagnosed complications associated with NOWS, and hospital length of stay) and
post-discharge health care utilization in the one-year follow-up period
Hypothesis 2: Markers of severity of NOWS, including, but not limited to, pharmacologic
treatment administered, use of adjunctive therapies (phenobarbital, clonidine), and LOS
will be associated with increased health care utilization over the one-year follow-up
period.
Aim 2 will be carried out through the following sub-aims:
2.A) To evaluate the relationship between NOWS severity measures and hospital
readmissions.
2.B) To evaluate the relationship between NOWS severity measures and
emergency department visits
2.C) To evaluate the relationship between NOWS severity measure and outpatient
visits.
1.7 Significance
The rates of NOWS in the United States has been constantly rising owing to the
opioid epidemic plaguing the country.43 A majority of the infants diagnosed with NOWS
will require treatment and longer hospitalization placing a significant burden on the
healthcare system.37,43 It is also important to note that almost 80% of the births associated
with OUD in pregnancy are paid for by Medicaid leading to an immense financial stress
on the social welfare system.25,44 While extensive studies have been conducted to minimize
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the burden on the health care system during the initial management of NOWS, the potential
long-term impact of such interventions has been relatively overlooked.26,27,29,39 Only a
single prior study used balancing measures such as 30-day all-cause readmission, 30-day
readmission related to NOWS, and death or unexpected ICU transfer within 30 days to
measure the long-term effectiveness of the intervention.45 Additionally, there are relatively
few studies that evaluated long-term health care utilization in infants born with NOWS. A
recent paper by Patrick et al. reported that infants with NOWS had a higher risk of hospital
readmissions compared to controls.36 However, the study did not include any information
on the medications that the infants received during their hospital stay. Prior report suggests
that variations exist in the treatment of NOWS, hence, detailed examination of treatment
received by the infant for NOWS and its association with post-discharge health care
utilization are critical.37
Our study expands on the work previously done by Patrick et al. by the addition of
variables that quantifies the treatment received by the infants for NOWS along with
severity measures of the condition. The administrative data used by Patrick et al. lacked
clinical data related to the treatment of NOWS which limited the study findings. The
availability of clinical information in the HF data overcomes those limitations by
elaborating on specific treatment received by the infants during the management of NOWS
and its effect on the health care utilization in the future. This study also provides a
comprehensive comparative summary of post-discharge health care utilization in infants
with and without NOWS. The model assessing the severity of NOWS (based on treatment
received, LOS and other variables) and post-discharge health care utilization will be a
valuable resource in developing interventions leading to improved health outcomes that do
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not merely focus on reducing hospital stay but also minimizing long-term adverse events
in infants born with NOWS.
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CHAPTER 2: LITERATURE REVIEW
2.1 Introduction
In this chapter, a detailed review of NOWS is presented. In the first section, a
description of NOWS will be provided, followed by an account of tools used to assess
NOWS. Next, we discuss the management of NOWS. These topics will provide us an
insight into the etiology, assessment, and treatment of NOWS in infants. Additionally,
further insight into how long-term outcomes may manifest in infants with NOWS is
provided. Finally, a detailed literature review of long-term health care utilization in infants
with NOWS is presented.
2.2 Neonatal opioid withdrawal syndrome
Opioids are natural, synthetic or semisynthetic compounds that act on the opioidreceptors (mu, kappa, and delta) in the central nervous system (CNS) to produce
analgesia.46 They also produce effects such as euphoria, sedation, and depression of
respiratory and gastrointestinal functions. Noradrenaline release is acutely inhibited in the
synaptic terminal due to long-term opioid use. However, the rate of noradrenaline release
in the synapses returns to normal after prolonged exposure and tolerance to opioid develops
in chronic users.32 Discontinuation of opioid use then results in abnormal release of
noradrenaline which produces the signs of withdrawal.
Opioids are lipophilic compounds that can cross the placental and blood-brain
barrier. Hence, prenatal opioid use affects the fetus. Active use of illicit opioids in during
pregnancy has been associated with adverse birth outcomes in the infant, such as low birth
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weight, and put the infant at additional risk because of other risky health behaviors related
to active substance use.47,48
Treatment with methadone or buprenorphine is a preferred treatment of OUD in
pregnancy and is designed to manage cravings, prevent withdrawal symptoms, and
minimize stress to the fetus.49 Pharmacological treatment is often accompanied by a wide
variety of prenatal care services that help to maintain physical and mental well-being of
the pregnant woman. While treatment with MAT, such as methadone, has substantial
benefits compared to illicit opioid use, it does not guarantee successful abstinence and
might be associated with significant, prolonged withdrawal effects in the newborn.32
A recently published systematic review concluded that the current evidence did not
support detoxification as a viable intervention in pregnancy as it increased the risk of
relapse.50 Wang et al. also reported that detoxification during pregnancy increased the risk
of relapse and illicit drug use.51 However, the study also concluded that detoxification
treatment did not affect the rates of NOWS or preterm birth.
Approximately 55 to 95% of the newborns with in-utero exposure to opioids
develop postnatal withdrawal or NOWS.32,52 NOWS is a complex physiological disorder
that involves the nervous system (central and autonomic) and gastrointestinal system of the
infant. While NOWS is a preferred term that defines opioid withdrawal in infants, the term
Neonatal Abstinence Syndrome (NAS) is also widely used to describe withdrawal in
infants. However, the term is not considered technically correct as the term “abstinence”
suggests “intention” and infants are not capable of intentional understanding or action.53 In
addition, NAS can refer to withdrawal syndrome associated with other drugs.
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Clinical manifestation of NOWS can be broadly classified into three categories: a)
metabolic, vasomotor, and respiratory, b) gastrointestinal and c) CNS.52-55 The first
category is associated with symptoms, such as fever, sweating, mottling, and tachypnea.
Gastrointestinal expressions are characterized by vomiting/regurgitation, diarrhea, weight
loss, and poor feeding. CNS manifestations are characterized by tremors, disturbances in
sleep, crying, irritability, and seizures. The symptoms of NOWS develop typically in 24 to
96 hours after birth; however, time of onset, and severity varies depending on multiple
factors. While time to onset of NOWS could have multiple predictors, dose and half-life of
the opioids that the infant was exposed to in-utero play a vital role in explaining the
variability. Symptoms may develop later in infants who were exposed to opioids with a
longer half-life period (e.g., methadone/buprenorphine) compared to opioids with a shorter
half-life period (e.g., heroin). Symptoms attributable to NOWS from heroin use are often
seen within 24 hours after birth. In comparison, symptoms of withdrawal from methadone
may occur 24 to 72 hours after birth.18 In buprenorphine exposed infants, the onset of
withdrawal is around 40 hours after birth.56,57 While NOWS is more common in infants
exposed to methadone compared to buprenorphine, studies have shown that up to 50% of
the infant exposed to buprenorphine develop NOWS.32,49,57,58 Factors, such as exposure to
other drugs, tobacco use, maternal nutrition, stress, opioid metabolism rates, and preterm
delivery, may also affect the severity of NOWS.59-61 Based on such observations, the
American Academy of Pediatrics has recommended an in hospital observation period of 3
to 7 days in neonates with in-utero exposure to opioids.32

12

2.3 Assessment of NOWS
Assessment of neonates who develop symptoms of NOWS is critical to quantify
the severity of withdrawal, thereby providing a guide to its management. Several tools have
been developed to help in the assessment of NOWS in newborns. The Finnegan Neonatal
Abstinence Scoring Tool (FNAST) was the first tool developed to assess the severity of
NOWS.52 It consists of 21 items and the possible score ranges from 0 to 62. Pharmacologic
management of NOWS is usually recommended if the infant scores more than or equal to
8 on three consecutive evaluations or 12 or more on two consecutive evaluations. While it
is the first and most widely utilized tool to score the severity of NOWS, it has been
criticized for its complexity and length.62 Additionally, lack of validation and suboptimal
inter-rater reliability of the tool are concerning.63 After the first Finnegan tool was
developed, three other scoring tools, i.e., The Lipsitz Neonatal Drug Withdrawal Scoring
System, the Neonatal Narcotic Withdrawal Index, and the Neonatal Withdrawal Inventory,
were developed between 1975 and 1998.64-66 They consist of a limited number of items (711) for simplicity and rapid administration. In 2010, the FNAST was modified into the
MOTHER NAS scale which was utilized in the MOTHER randomized clinical trial
study.49 It is a 19-item scale with scores ranging from 0 to 42; the score required for
treatment initiation is 9 or higher. In 2013, a shorter version of the FNAST, called the
Finnegan Neonatal Abstinence Syndrome Scale-Short Form, was developed. It allows for
faster assessment with fewer items and consists of 7 items with scores ranging from 0 to
16.67 Treatment initiation with opioids is recommended at a score of 8 or higher. Recently,
another approach, called Eat, Sleep, and Console (ESC), was developed by Grossman et
al. for evaluation and treatment of infants with NOWS.26 It utilizes a novel approach that
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evaluates three criteria: eating (infant was able to eat ≥ 1 oz. per feed), sleeping (infant was
able to sleep undisturbed ≥1 hour), and consoling (infant was able to be consoled within
10 minutes if crying). Infant meeting these criteria is considered “well managed” and
requires no further intervention. Evidence from recent studies support ESC method to
minimize exposure to pharmacological treatments and decrease the LOS.68
Another tool, known as the Neonatal Network Neurobehavioral Scale (NNNS) part
II (Stress and abstinence scale) was developed in 2004.69 The NNNS is a comprehensive
instrument developed to examine outcomes in newborn after prenatal exposure to drugs.
The stress/abstinence scale of the NNNS consists of 7 categories and consists of fifty items.
It is important to note that this tool was not developed to be used as a guide for the treatment
of NOWS but rather as a comprehensive newborn evaluation.
2.4 Management of NOWS
The objective of management of NOWS is to promote growth and development of
the infant. Particular importance is given towards minimizing distress, improving food
intake, and promoting mother-child bonding. While NOWS has been managed for over
four decades there is lack of consistency in management protocols across different
hospitals. In general, care to infant diagnosed with NOWS should include a
multidisciplinary approach that includes non-pharmacologic and pharmacologic
management based on the needs of the mother-infant dyad in an environment that is nonjudgmental and fosters mother-infant bonding.70 It is essential to note that the creation of a
safe environment for the mother is equally important as there is significant stigma related
to opioid use and withdrawal effects in the infants. Also, active participation of mothers in
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the healing process by rooming-in and breastfeeding (when appropriate) has shown to
benefit the mother-infant dyad.63,71 Since maternal characteristics (e.g.: polysubstance use,
presence of other comorbidities, low socio-economic status, stress, poor nutrition etc.) and
environment are considered risk factors for poor health outcomes in those infants, postpartum support mechanism for the mother may be required to ensure the adequacy of care
in the newborn.
2.4.1 Non-pharmacologic care
Infants who are prenatally exposed to opioids initially receive supportive care. Such
care involves creating a gentle non-stimulating environment to calm the infant and promote
rest.32,53,59,63 It involves minimizing exposure to stimuli, such as light and noise,
minimization of handling, promoting feeding to improve weight gain, and resting.32 While
several alternative care methods, such as massage and cuddling, have been utilized in the
management of infants with NOWS, those intervention have not been rigorously assessed
for their efficacy in reducing severity of NOWS. There is consistent evidence that supports
breastfeeding and rooming-in to improve outcomes associated with NOWS.71,72 Infants
who were breastfed were shown to require less treatment with opioids and had a shorter
LOS compared to infants who had received formula.73,74 Unfortunately, rates of
breastfeeding in mothers receiving treatment for OUD are low.75 It is important to note that
breastfeeding is contradicted in mother with HIV infection and illicit drug use, and such
conditions are common in OUD. Additionally, infant exposure to opioids continues
through breast milk, even though in very small amounts. Although the benefits of
breastfeeding and rooming-in have been shown consistently, potential barriers to their
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implementations, such as differences in the practice setting, unavailability of resources,
and reluctance to introduce new practices, exist.53
2.4.2 Pharmacologic treatment
More than two-thirds of the infants with NOWS have limited response to nonpharmacologic management and hence require pharmacologic treatment for the
management of the symptoms.23,53 The rationale behind the use of pharmacologic treatment
is short-term management of the symptoms, such as seizures, fever, and weight loss
associated with NOWS, as drug withdrawal is self-limiting in nature.32 There is significant
variation in the management of NOWS and there is no specific standard of care that is
widely accepted in relation to dosing, treatment initiation or use of adjunctive therapies.37
There is a consensus on the use of oral morphine or methadone as first-line agents for the
management of NOWS.33 Morphine is a short-acting mu-opioid receptor agonist, and
methadone is a much longer acting synthetic mu-opioid receptor agonist. While these
medications have been consistently shown to be effective in the management of NOWS,
their use is often associated with longer hospital stays. Side effects, such as sedation and
depression of respiratory functions, are also common.23,53 Studies also report that
regardless of the opioid used for the treatment of NOWS, a structured protocol for
treatment is significantly likely to lower treatment days, LOS, and result in lower doses of
opioid administered to the infant.76,77
Adjunctive agents, such as phenobarbital and clonidine, are used if the infant fails
to respond to the first-line agents. There are no specific guidelines for the addition of these
second-line agents in the management of NOWS.38 Studies on long-term safety and
efficacy of these agents are also currently lacking.29
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2.5 Long-term neurobehavioral and clinical outcomes associated with NOWS
There have been several reviews that highlight long-term neurobehavioral and
clinical outcomes associated with prolonged in-utero opioid exposure in infants.67,78,79
Studies have reported that problems with vision, such as strabismus, reduction in visual
acuity and other impairments, are related to opioid exposure.80-82 Research on behavioral
and cognitive development in infants born to mother with OUD show conflicting results.
Two reviews which consisted of studies published prior to 2016 report poor behavioral and
cognitive outcomes in infants prenatally exposed to opioids.78,83 However, recent studies
on infants born to women on methadone or buprenorphine therapy showed that these
infants had normal neurobehavioral development in early infancy.84,85
2.6 Long-term health care utilization in infants diagnosed with NOWS
We conducted a literature review to identify published studies that reported on
long-term health care utilization associated with NOWS. We searched PubMed/Medline
database using keywords related to long-term health care utilization and neonatal
abstinence syndrome/neonatal opioid withdrawal syndrome as stated below:
“((((((((((long-term outcome) OR long-term outcomes)) OR hospital readmissions) OR 30day hospital readmissions) OR emergency department visits) OR urgent care visits) OR
healthcare utilization) OR outpatient visits)) AND ((((((neonatal abstinence syndrome) OR
neonatal opioid withdrawal syndrome) OR opioid neonatal abstinence syndrome) OR
neonatal abstinence) OR neonatal drug withdrawal syndrome) OR neonatal drug
withdrawal)”.
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Since there were limited articles that specifically evaluated long-term health outcomes
and health care utilization in infants with NOWS, we also included studies that evaluated
these outcomes infants with in-utero opioid exposure. This allowed for comparison of
outcomes in infants with NOWS with infants who had in-utero opioid exposure regardless
of the diagnosis of NOWS. The inclusion criteria for the literature review included:
1) Study

investigating

long-term

health

NOWS/NAS/maternal opioid exposure
2) Human studies
3) Studies published in English
The exclusion criteria for the review included:
1) Literature review
2) Comment on a published article
3) Withdrawal unrelated to opioids
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care

utilization

associated

with

Figure 1: PRISMA flow diagram for literature review

Based on our search criteria, our initial search led to the identification of 131 studies
(Figure 1). Of these studies, 24 studies that were relevant to the literature search were
identified and were further screened. Three articles were selected from the 24 studies after
evaluation. Three more studies/reports were identified after reviewing the references in
selected studies. In the sections below 6 articles that evaluate long-term health care
utilization in infants born with NOWS/NAS are described (Table 1).
Cordelie E.W. evaluated the association between NAS and long-term health
outcomes.35 Using a retrospective cohort design, the researchers studied infants born in the
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state of Washington between the years 1990 and 2008 evaluating the risk of hospital
readmissions in infants with and without NAS. The follow-up period was five years after
discharge from the hospital. The study reported that infants diagnosed with NAS were at a
significantly higher risk of hospital readmission compared to unexposed infants even after
controlling for factors such as maternal age, education, gestational age, and smoking. After
adjustment for the confounders, the authors reported that infants diagnosed with NAS had
a higher risk of hospital readmission associated with a) infectious and parasitic diseases, b)
diseases of the nervous, gastrointestinal and genitourinary system, and c) injury by another
person, neglect or abuse.
Stephen W.P. et al. evaluated the risk of hospital readmission in infants who were
diagnosed with NAS.36 The study utilized administrative data for all the births in the state
of New York from 2006 to 2009 to identify infants with a NAS diagnosis and two
comparison groups - uncomplicated term births and late preterm births. After adjusting for
confounders, the study showed that there was a higher risk of 30-day hospital readmission
in the infants with NAS compared to infants with uncomplicated term births. They also
stated that the readmission rates were similar to late preterm infants. Additionally, infants
who received a diagnosis of NAS but were discharged in less than a week since birth had
a higher 30-day hospital readmission rate.
Tamara C. et al. reported on the child health services utilization in children born to
119 mother with substance use disorder (self-reported use of methadone, amphetamine or
opiates) in the period between 2000 and 2003 in Australia.86 They reported that
approximately 29% of the children who were born to mothers with substance use disorder
did not access standard health services in their first two years of life. Additionally, use of
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child health services was associated with lower child protection notification for mothers
who were on methadone compared to other substances.
Kirsimarja R. et al. conducted a population-based retrospective cohort study in
Finland to evaluate hospitalizations and “out-of-home” placements in children whose
mothers abused substances.87 The authors followed 55,369 infants born in Finland in 2002
for the first seven years of their lives. The study reported higher rates of injury, infectious
diseases, hospital treatment for other reasons, and out-of-home placement in children of
born to women with substance use disorders (n=205) compared to controls (no substance
abuse, n=54,291). While these associations (hospitalization) were significant in unadjusted
analysis, they remained significant in the adjusted analysis only in subjects who also had
concomitant alcohol use. Out-of-home placement was significant (OR: 7.4, 95% C.I.: 5.210.5) even after adjustment of confounders. In the adjusted model, the study controlled for
factors such as child’s sex, mother’s psychiatric condition, relationship status, education,
and social assistance status.
Hannah U. et al. used a population-based retrospective cohort study to evaluate
causes of hospitalization in children who were diagnosed with NAS at birth.88 The study
followed children born between the years 2000 and 2011 in New South Wales for 13 years.
They identified 3,842 infants who had received a diagnosis of NAS; the comparison group
included 1,018,421 infants who did not have NAS diagnosis. The study reported that
infants with NAS had a higher risk of hospitalizations (OR: 1.6, 95% C.I.: 1.5-1.7). The
reasons for hospitalization constituted mainly of assault, maltreatment, and poisoning.
Physiological reasons for hospital readmission were mental and visual disorders. After
accounting for other confounders, NAS was found to be a significant predictor of
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readmissions related to maltreatment (OR: 4.5, 95% C.I.: 3.4-6.1), and behavioral disorders
(OR: 2.3, 95% C.I.: 1.9-2.9).
A short report by Savin M. described health care utilization during their first year
of life in infants who were diagnosed with NAS using the Delaware Medicaid data.34 Four
hundred and ninety-nine infants who received a diagnosis of NAS were identified between
the years 2012 and 2014. The study reported that approximately 15% of the infants required
hospital readmission. There was a decreasing trend in well-child visits from 38% at six
months to 30% at 9 months. Fifty-two percent of the infants had emergency department
visits and 7% had urgent care visits. This report, however, lacked a control group for
comparison.
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Table 1: Summary of articles that evaluate long-term health care utilization in infants with NOWS/NAS or maternal exposure to opioids
Author

Year

Study design

Study
population
Infants born
in
Washington
state (19902008)

Database

Witt CE et
al35

2017

Retrospective
cohort study

Patrick
SWS
et
al.36

2016

Tamara C
et al. 86

2011

Exposed
group
Infants
diagnosed
with
NAS
(n=1,900).
Identification
by
ICD-9CM
code
779.5

Control

Outcomes evaluated

Results

Unexposed
(n=12,283).
Did not receive
NAS
diagnosis,
neither
had
diagnosis
codes
that
indicated
maternal
opioid
dependence

During the first five
years of life after
discharge
Hospitalizations
Infant mortality

Adjusted
relative
risk
All-cause readmission: 1.54
(1.37-1.73)
All-cause death: 1.94 (0.993.80)

Retrospective
cohort study

Infants born
in
New
York State
(20062009)

New
York
State Inpatient
Database from
Healthcare
Cost
and
Utilization
Project

Infants
diagnosed
with
NAS
(n=1643).
Identification
by
ICD-9CM
code
779.5

Uncomplicated
term
births
(n=700,643)
and
late
preterm births
(n=51,748)

30-day
hospital
readmission
after
discharge

Adjusted relative risk for
infants diagnosed with NAS
30-day
hospital
readmission: 2.49 (1.753.55)

Retrospective
cohort study

Maternity
admissions
to
Royal
Brisbane
Women's
Hospital
(20002003)

NA

Mother who
self-reported
methadone,
amphetamine
or opiate use
(n=119)

NA

During a follow-up of
2
years:
Child
protection
(harm:
emotional,
physical,
neglect)
Child
health
(engagement
with
any child services)

Approximately twenty nine
percent of the children did
not have any child health use
in first 2 years of life.

Comprehensive
Hospital
Abstract
Reporting
System
in
Washington
State.
Data
from
both
mother
and
infant
was
obtained
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Kirsimarja
R et al. 87

2015

Population
based
retrospective
cohort study

Infants born
in Finland
(2002)

Medical Birth
Register
(9
additional
registers
for
other detailed
information)

Mothers with
registry entry
related
to
substance
abuse (19982009)
(n=202 for
drug abuse)

Mothers
without
registry entry
substance
abuse
(n=53,457)

During a follow-up of
7
years:
Hospitalizations
Out-of-home
placements

Significant difference (drug
abuse compared to controls)
in unadjusted rates of:
Injury (8% vs. 4%)
Infectious disease (10% vs.
7%)
Hospital treatment for other
reasons (51% vs. 36%)
Out-of-home care (38% vs.
1%)

Hannah
U88

2015

Population
based
retrospective
cohort study

Infants born
in
New
South
Wales
(20002013)

Linkage
of
Perinatal Data
Collection,
Admitted
Patient
Data
Collection,
Australian
Bureau
of
Statistics Cause
of
Death,
NICUS Data
Collection

Infants
diagnosed
with
NAS
(n=3837).
Identification
by ICD-10
code p96.1.

Infants without
NAS
(n=1,016,565)

During a follow-up
for a maximum of 13
years:
Hospitalizations
Reasons
for
hospitalizations

Risk of outcomes compared
to controls:
Rehospitalization (OR: 1.6,
95% C.I.: 1.5-1.7)
Mortality during
hospitalization (OR: 3.3,
95% C.I.: 2.1-5.1)
Reason for hospitalization:
Assaults, maltreatment,
poisoning, behavioral
health, vision problems.

Savin M34

2017

Retrospective
study

Infants born
in Delaware
(20122014)

Delaware
Medicaid data

Infants
diagnosed
with
NAS
(n=499).
Identification
by
ICD-9CM code

NA

During the first year
of
life:
Emergency
department
visits
Urgent Care visits
Primary care provide
visits
Well child visits

Health
care
service
utilization
rates:
Inpatient:
15%
Emergency
department:
52%
Urgent
Care:
7%
No vaccinations: 8% of
infants
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From the studies above, we can conclude that there is increased health care
utilization in infants with a NAS/NOWS diagnosis or those exposed to opioids prenatally.
The studies show increased need for care and follow-up services in infants who received
such diagnoses. While these studies have shown that withdrawal syndromes can have farreaching consequences, the results of the studies lack clinical data and are generalized to
specific regions. Additionally, most of these studies were not nuanced to capture the
specific details of health care utilization, such as emergency department visits and
outpatient visits. Inpatient visits are more likely in infants who were diagnosed with
NAS/NOWS as noted by those studies, but well-child visits and child care services have
been shown to be underutilized. Our study addresses many of these limitations. First, the
dataset represents a diverse population. Second, it evaluates a broader range of health care
utilization events. Finally, it also incorporates clinical data derived from the electronic
health records in the analysis.
Likewise, prior studies have not specifically focused on the treatment received by
the infants after birth during their hospital stay and how it could potentially affect health
care utilization in the long run. Opioids used for the treatment of withdrawal symptoms
and adjunctive therapy may have a long-term effect on the infants that may lead to
increased health care utilization. Since a large variability in treatment protocol exists, it is
essential to know how such differences might affect long-term health care utilization.
Further, studies that focus on the management of NOWS have primarily focused on
minimizing the exposure to opioids and LOS in the hospitals without accounting for
hospital readmission rates and health care utilization in the future.35,36 This might lead to
increase in rates of hospital readmission in infants who were diagnosed with NOWS. In
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some infants, the full symptoms of NOWS could possibly manifest after 4-5 days; any
discharge before that period could lead to further health care utilization in terms of
emergency department visits. For example, the study by Patrick et al. demonstrated that
the rate of emergency department visits are higher in infants with NAS who were
discharged before one week since birth compared to those discharge after one week.36
Additionally, it is important to be able to compare long-term health care utilization
of infants with NOWS to other medical conditions that are known to be self-limiting in
nature, but are associated with higher health care utilization. Late preterm infants are born
at a gestational age of 33 weeks or higher but less than 37 weeks.89 These infants are known
to be physiologically “immature”. They are at a higher risk of morbidity, mortality, and
hospital readmission compared to term birth infants.89 These infants may exhibit symptoms
similar to infants with NOWS, such as respiratory distress and feeding difficulties during
their birth hospitalization, although the mechanisms vary greatly from infants with NOWS.
Late preterm infants can serve as an efficient control group for infants with NOWS.
Therefore, it was included in our study as secondary control group
While it is important to note that long-term outcomes are difficult to ascertain given
that there are several factors (environmental and social) associated with OUD, the current
gap in the literature regarding long-term health care utilization and treatment received
during the management of NOWS should be explored. Understanding the differences in
health care utilization in infants who were diagnosed with withdrawal syndrome and
evaluation of their health care utilization will lead us to better understand the long-term
consequences of NOWS. It is imperative that proper follow-up of the mother-infant dyad
is maintained to promote child safety and health. In the context of the current opioid
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epidemic in the United States, our study will be able to specifically estimate the long-term
burden of NOWS which can help in planning intervention or allocation of specific
resources for combating the affliction.
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CHAPTER 3: METHODS
3.1 Introduction
In this chapter, approach to the analysis of data to test our hypothesis is outlined.
This section begins with the description of the data source that was used in the study,
followed by the study design, and inclusion and exclusion criteria for sample section. Then
the methods for each Specific Aim are described, including methodology for identification
of outcome and exposure variables. Finally, statistical methods used in the analysis are
described which is followed by power analysis for sample size calculations.
3.2 Data source
The Cerner Health Facts® database was utilized to assess the differences in postdischarge health care utilization in infants born with NOWS compared to controls during
a one-year follow-up period. HF is a national database warehouse that collects extensive
clinical data across hospitals in the United States that utilize the Cerner EHR System. The
database includes encounter data consisting of emergency, outpatient, and inpatient visits.
Further, information on provider specialty, hospital procedures, diagnoses, laboratory, and
pharmacy data are included in the HF database. Additionally, patient demographic
information, such as age, sex, and race, along with hospital characteristics, such as
specialty, acute care, number of beds, census region, and location (urban or rural), are
available. HF database is de-identified and HIPAA-compliant which allows for protection
of both patient’s and organization’s identity. The database is longitudinal and continuity of
patient encounters, if it occurred within the same health system, is preserved. This allows
for efficient follow-up of patients after discharge when they seek health care in the same
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health system. HF database consists of records from over 500 health facilities in the United
States with records dating back over two decades. IRB approval from the University of
New Mexico Health Sciences Center Human Research Protection Office was obtained for
this study.
For purposes of this analysis, HF data between the January 1, 2011 and September
30, 2017) were used. This time captures the increasing rates of opioid use in the U.S. and
subsequent increase in the rate of NOWS.90
3.3 Study design
Our study utilized a retrospective cohort study design. The study population
consisted of all the births recorded in the HF database between January 1, 2011 and
September 30, 2016. Study cohort was sampled from the study population based on
inclusion/exclusion criteria listed in the sections below. Retrospective cohort study design
allowed for examination of several outcomes in the given sample.
3.4 Study population
3.4.1 Selection criteria for infants diagnosed with NOWS (exposed group)
Inclusion criteria:
Infants diagnosed with NOWS were identified using the International
Classification of Diseases, Ninth Revision (ICD-9-CM) diagnostic code 779.5 and ICD-10
diagnostic code P96.1, which denote drug withdrawal syndrome in infants. Encounter
identification number (EIN) is a unique identification number assigned to a specific
encounter of a patient with the health care system. Based on the EIN, patient number for
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that specific visit was determined and traced back to the unique patient identification
number (PIN). The unique PIN was used to follow-up the cohort to assess their postdischarge health care utilization. The follow-up assessment period began on the discharge
date associated with the encounter that was related to NOWS and ended after 365 days.
Exclusion criteria:
We excluded infants whose initial LOS after birth was less than 3 days. This
criterion was used following the rationale that infants with suspected NOWS often have a
required observation period of 72 to 96 hours.32,91,92 Previous studies have also reported
that adding an additional criterion regarding LOS could improve the identification of
infants with NOWS.93 We also excluded infants whose age at first encounter was more
than 4 days. This period was chosen to account for any infants with NOWS who were
transferred into a CERNER facility but not born in that hospital. Critically-ill neonates are
often treated with opioids which may result in iatrogenic withdrawal syndrome. Since the
objective of the study is to evaluate health care utilization in infants with NOWS
subsequent to in-utero exposure to opioids, we excluded infants with following conditions:
lung disease, intraventricular hemorrhage, periventricular leukomalacia, necrotizing
enterocolitis, spontaneous bowel perforation, congenital anomalies, and those that required
critical oxygenation (Table 2). These diagnoses are presumed to be linked with iatrogenic
NOWS.25,36,37 Infants with early preterm birth (gestational age at birth less than 33 weeks)
were also excluded as they could potentially have a much longer hospital stay and have a
large set of comorbidities. Infants with total LOS of more than 60 days were also excluded
from this study group as outliers. We also excluded patients whose discharge summary
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denoted that the patient had passed away or if they were transferred to a health
center/hospital.
3.4.2 Selection of the control groups:
Uncomplicated births:
Uncomplicated births were identified using ICD-9-CM code V30.x and ICD-10
code Z38.0 which apply to “Single liveborn, born in hospital, delivered without mention
of cesarean section.” We excluded infants with LOS less than 0 days (to account for
inaccuracies in information regarding LOS) and infants whose age at first encounter was
more than 4 days. Additionally, infants with initial LOS of more than 3 days were also
excluded. Prolonged hospital stay after birth is a marker for an underlying condition that
could require clinical observation, tests or management. Exclusion of infants with LOS
longer than 3 days ensured that such cases were excluded from the uncomplicated birth
study group. We also excluded infants who had received additional diagnosis of NOWS,
diagnosis codes related to iatrogenic NOWS, or any preterm birth (gestational age less than
37 weeks) from this group. Patients whose discharge summary denoted that the patient had
passed away or if they were transferred to a health center were also excluded.
Late preterm births:
Infants with late preterm births served as secondary controls to the exposed group.
These infants are susceptible to adverse health outcomes and have increased hospital
readmissions compared to term infants, but are not as ill as very preterm infants.41,42,94
These infants were identified using the ICD-9-CM codes 765.27 and 765.28 (ICD-10:
P07.36- P07.39), which represent gestational ages greater than or equal to 33 weeks and
less than 37 weeks.89 Since infants with NOWS are likely to be born preterm, these two
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study groups were devised to be mutually exclusive, i.e. infants diagnosed with NOWS
were not categorized as late preterm birth. Infants with LOS less than 0 days were excluded
from this study group. We also excluded infants whose age at the encounter was more than
4 days. Furthermore, we excluded patients whose LOS was more than 60 days. We also
excluded patients whose discharge summary denoted that the patient had passed away or
if they were transferred to a health center.
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Table 2: Conditions for inclusion and exclusion criteria for sample selection and
corresponding diagnostic codes (ICD-9-CM and ICD-10-CM)
Condition
NOWS/NAS
Late preterm births
Preterm
newborn,
gestational
age
33-34
completed weeks
Preterm
newborn,
gestational
age
35-36
completed weeks
Single live-born, born in
hospital, delivered without
mention of cesarean section
Exclusionary codes
Chronic respiratory disease
arising in the perinatal
period
Intraventricular hemorrhage
of fetus or newborn
Periventricular
leukomalacia
Intracranial injury of other
and unspecified nature
Necrotizing enterocolitis in
newborn
Perinatal
intestinal
perforation
Early preterm, gestational
age less than 33 weeks

ICD-9-CM
779.5

ICD-10-CM
P96.1

765.27

P07.36, P07.37

765.28

P07.38, P07.38

V30.00

Z38.0

770.7

P27.X

772.1X

P52.X

779.7

P92.1

854.XX

S06.90XA, S06.89XA

777.5X

P77.1-3, P77.9

777.6

P78.0

765.21-765.26

P07.21- 26, P07.31-35
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3.4.3 Detailed description of the sample selection process for the study
HF dataset was accessed using a secure access point at the University of New
Mexico Clinical and Translational Sciences Center. The database consists of several data
tables linked through a primary encounter identification number. To account for the large
number of observations across several years that spans three different cohorts, the initial
data cleaning process was divided based on the study group and the year of the encounter.
Using Postgres SQL, the first selection criterion was applied to identify the study groups.
For example, infants with NOWS were identified using the type of code (ICD-9 or
ICD-10) and the diagnosis code (779.5 or P96.1) from the “diagnosis and procedure
specific information table”. Additionally, the selection criteria were also restricted to
discharge between specific time period (e.g., discharges between 2011 and 2012). For
simplicity, the dataset created in this step will be referred to as “base set” in the manuscript.
After the specific EINs were collected for the specific study group and for a specific
year (or time period), unique PIN associated with the EIN for each infant in the base set
was identified. These PINs were then used to collect all of the encounter related
information of an infant for a period of one year starting at the initial index period for the
search. For simplicity, the dataset created in this step will be referred to as “complete set”
in the manuscript.
The dataset that was created (complete set) contained information on diagnostic
codes, age that the specific encounter, hospital information (census region, census division,
bed size range, urban-rural status), patient type, care-setting, admit date, discharge date,
admission type, discharge description, and information on the infant (race, sex). The
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dataset thus created was in a long form, i.e. each encounter along with any number of
diagnostic codes or information that varied across that specific encounter were presented
in different rows. These individual data files were exported as *.csv file and processed in
STATA (version 14, College Station, TX).95
The raw dataset extracted from the full HF database was processed in five steps
which are described below (illustrated in Figure 2):
a) Preprocessing: Exclusion based on LOS and age at encounter criteria and identification
of specific encounter id.
First, raw encounter data (base set) were imported into STATA; the duplicates
were removed. Next, LOS variable was created. This variable was calculated
by subtracting the date of admission from the date of discharge. Following this
step, exclusion criteria were applied based on the study group (Table 3).
Table 3: Exclusion criteria based on age at primary healthcare encounter and LOS
NOWS

Late preterm birth

Uncomplicated birth

Age at encounter more

Age at encounter more

Age at encounter more

than 4 days

than 4 days

than 4 days

LOS less than 3 days

LOS less than 0 days

LOS less than 0 days

-

-

LOS more than 4 days

-

-

Patient care setting:
NICU/ICU

After the application of these exclusion criteria any remaining duplicate
encounter IDs were excluded and a base encounter ID set was created.
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b) Identification of the primary encounter and associated diagnostic codes. Application of
diagnostic codes based exclusion criteria.
The base encounter ID set was merged with the “complete set” and matched
records were retained. The resulting dataset was in a long form and contained
all the primary visit related information. This dataset was converted to a wide
form (diagnostic codes from rows to columns). Following the transformation,
diagnostic codes based exclusion criteria were applied (Table 4). This set will
be referred to as “baseline encounter set” for future reference.
Table 4: Exclusion criteria based on diagnostic codes and LOS
NOWS

Late preterm birth

Uncomplicated birth

Iatrogenic NOWS

Iatrogenic NOWS

Iatrogenic NOWS

Early preterm

Early preterm

Any preterm

(Gestational age <33

(Gestational age <33

(Gestational age <37

weeks)

weeks)

weeks)

Diagnostic codes for

Diagnostic codes for

NOWS

NOWS

LOS more than 60

LOS more than 60

-

days

days

Exclusion criteria

After the application of the exclusion criteria, unique patient identification
numbers were selected from the dataset to identify infants who would be
eligible for follow-up.
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c) Identification of the follow-up visits using the unique patient identification code.
Quantification of the outcome variables (post-discharge health care utilization) and the
time to events for a specific outcome.
The unique patient identification number set was merged with the “complete
set” and the matched records were retained. This dataset consisted of all the
encounter related information with the PIN across multiple health related
encounters in a long format. The dataset was converted to a wide format
accounting for the diagnosis code related to each encounter. Next, the dataset
was sorted using the admit date and PIN. Time-to-event variable was created
by subtracting unique date of admission/ date of event (post-discharge events)
from the date of discharge related to the primary visit. An event counter variable
was created to calculate the number of post-discharge health care utilization
event. Since the above algorithm would also create a time-to-event for the
baseline (which would be equal to the LOS), the value was specified as zero.
The value zero for the time-to-event marked the primary/baseline health
encounter. Next, the follow-up event or post-discharge health care utilization
event were categorized into 3 variables (Inpatient, Emergency, Outpatient)
using the patient care-setting and patient type variables originally present in the
HF database. These new variables were retained along with EIN and PIN to
create a temporary dataset. The temporary dataset was transformed to a wide
format. After the conversion, each unique patient (observation unit) had all the
health care utilization events in a single row. Following this step, binary
variables were created for presence of each event (Inpatient, emergency,
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outpatient) for event taking place within 365 days of discharge. This set will be
referred to as “outcomes set” in the manuscript.
d) Merging initial encounter information (baseline data) with the post-discharge health
care utilization data.
The baseline information form “baseline encounter set” was merged with the
“outcomes set” using the unique patient identification number. Duplicate
matches were excluded.
e) Merging data across study group and study years to get a final working database for
statistical analysis.
Data across all the study group for all the study period were appended. The data
from the uncomplicated group consisted a 25% random sample (randomly
sampled from each year). Additional exclusion criteria for infants who were
recorded as “Expired” or “Readmitted” in the initial visit discharge summary
was applied during this step. Finally, a second reexamination for duplicate
encounters or unique IDs was performed and duplicates were removed.
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Figure 2: Graphical illustration of the data cleaning, merging, and modification for the
study
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3.5 Aim 1: To compare and characterize post-discharge health care utilization of infants
born with NOWS compared to controls (uncomplicated births and late preterm births)
during a one-year follow-up period.
For Aim I, the study cohort was identified, as previously described. The follow-up period
for the cohort began at the time of discharge and ended at 365 days after discharge (Figure
3).
3.5.1 Outcomes
The outcomes of interests are described in the following section (Table 5). For Aim
1.A, the outcome of interest was post-discharge hospital readmission. These visits were
assessed using the patient type and patient discharge care setting variable in the HF
database. Hospital readmission was operationalized using four different variables. First
was an indicator variable for any readmission within 30 days of discharge. Second was any
readmission during the total follow-up period of 365 days. Third was the total number of
readmissions during the study period. Lastly, we calculated time to first hospital
readmission as the fourth outcome variable.
For Aim 1.B, the outcome of interest was post-discharge emergency department
visit. These visits were assessed using the patient type and patient discharge care setting
variable. Emergency department visit was operationalized by four different variables. First
was an indicator variable for any emergency department visit within 30 days of discharge.
Second was any emergency department visit during the total follow-up period of 365 days.
Third was the total number of emergency department visits during the study period. The
fourth was time to first emergency department visit.
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For Aim 1.C, the outcome of interest was outpatient visits. They were characterized
similarly using patient type and patient discharge care setting variable in the HF database.
Outpatient visits were operationalized by two variables. The first was any outpatient visit
during the study period and the second was total number of outpatient visits.
Additionally, we constructed “any composite visit” (expressed as “any visit” in the
tables in result section) variable which was a composite of any emergency department visit
or hospital readmission to account for the possibility of one visit affecting other type of
visits.
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Figure 3: Overview of study design for Aim 1
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Table 5: Description of the outcome variables for Aim 1
Sub-

Description of the outcome variable

Type of variable

aim
1.A

All cause 30-day hospital readmission

Binary

1.A

All cause hospital readmission during the study period

Binary

1.A

Total number of hospital visits during the study period

Count

1.A

Time to first hospital readmission

1.B

All cause 30-day emergency department visits

Binary

1.B

All cause emergency department visit during the study

Binary

Continuous

period
1.B

Total number of emergency department visit during study

Count

period
1.B

Time to first emergency department visit

Continuous

1.C

Any outpatient visit during the study period

Binary

1.C

Total number of outpatient visit during study period

Count

3.5.2 Covariates:
We controlled for the infant sex, race, type of insurance, hospital location (urban or
rural), hospital census division, year of primary encounter, and the hospital bed size as
socio-demographic variables related to initial care. Furthermore, medical conditions, such
as respiratory problems, feeding difficulties, jaundice, and sepsis, were also considered as
possible covariates. Table 6 and 7 presents the operationalization of these variables.
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Table 6: Operationalization of demographics and patient care setting covariates
Variable

Operationalization

Sex

Binary (Male and Female)

Race

Categorical (Caucasian, African
American, Hispanic, Native American,
Others)

Insurance

Categorical (Medicaid, Commercial,
Others)

Census division

Categorical (1,2,3,4,5,6,7,8,9)

Urban rural status

Binary (Urban, Rural)

Bed size

Categorical (Less than 100, 100-299,
Greater than 300)
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Table 7: Operationalization of medical diagnostic codes present at the primary health
encounter
Condition
Respiratory problems
Respiratory distress
syndrome of newborn
Transient tachypnea of
newborn
Respiratory condition of
newborn, unspecified
Other specified respiratory
conditions of newborn

ICD-9-CM

ICD-10-CM

769

P22.0

770.6

P22.1

770.9

P28.9

770.89

P28.89

783.3, 779.31

P92.1-2, P92.8-9

Jaundice

774.XX

P58.XX, P59.XX

Sepsis (Bacterial sepsis of
newborn)

771.81

P36.9

Feeding difficulties

3.6 Aim 2: To evaluate the relationship between NOWS severity measures (pharmacologic
management of NOWS, use of adjunctive therapy, concurrently diagnosed complications
associated with NOWS, and hospital length of stay) and post-discharge health care
utilization in the one-year follow-up period
Study sample:
For Specific Aim 2, the sample size was restricted to infants who were diagnosed
with NOWS at birth. They were selected based on the inclusion and exclusion criteria
described previously in section 3.5. The overview of the study design is presented in Figure
4.
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Figure 4: Overview of study design for Aim 2
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3.6.1 Measures of NOWS severity as predictors of post-discharge health care utilization
The objective of Aim 2 was to evaluate the impact of pharmacological management
of NOWS, LOS, adjunctive therapy, prematurity, other diagnostic codes associated with
NOWS associated with hospital stay during the treatment of NOWS on health care
utilization during the one-year follow-up period. These variables represented the severity
of NOWS in the infant. Pharmacological management of NOWS was described as infant
receiving either morphine, methadone, tincture of opium or phenobarbital during the initial
hospital stay. Since phenobarbital is also widely used as a second line therapy, its impact
on post-discharge health care utilization was also assessed independent of opioid treatment.
LOS was calculated as the difference between the infant’s date of birth and the discharge
date associated with treatment for NOWS. Other medical conditions, such as respiratory
problems (presence of any of the conditions listed in Table 7) and feeding difficulties were
considered as other factors relating to severity of NOWS. Furthermore, benzodiazepines,
administered during the initial hospital stay were also considered as markers of NOWS
severity.
3.6.2 Operationalization of NOWS severity factors
i. Identification of infants who received pharmacological treatment for NOWS
As described previously, infants who received morphine, methadone or
phenobarbital during their initial stay in the hospital were classified as infants who received
pharmacological treatment for NOWS. Medication used during the baseline hospital stay
in infants with NOWS was assessed using the medication facts table in the HF database.
First, all the encounters related to baseline visits were ascertained. Using those EIN,
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medications used during that specific visit was identified. Medication classes were grouped
as following: a) medications for treatment of NOWS (methadone, morphine, tincture of
opium, phenobarbital) and b) benzodiazepines (lorazepam, alprazolam, clonazepam
diazepam or midazolam).
ii. Length of hospital stay
LOS after birth is usually considered a factor that could affect short term postdischarge healthcare utilization.36 Length of hospital stay is a function of infant health at
birth, i.e., presence of any medical conditions at birth can potentially lead to prolonged
hospital stay. However, there could also be another mechanism where shorter LOS could
lead to increased health care utilization. This could be explained in the case where a
medical condition could potentially go undetected during the initial hospital stay which
could lead to prompt return to a health care facility following a discharge. Furthermore, it
cannot always be assumed that longer hospital stay is associated with poor health. For
example, infants treated with methadone or morphine could have different LOS owing to
the tapering schedule for the medication they received. Hence, the effect of the LOS on
NOWS severity may not be linear. To examine if the effects of LOS are non-linear on
short-term post-discharge healthcare utilization (30-day rehospitalization, emergency or
composite visit), the following transformation of LOS were examined:
a. LOS in linear form:
In this model, the LOS was used in its original form.
b. LOS in quadratic form:
In this model, the LOS was used in a quadratic form, i.e., a normal form and a squared
form of LOS were used as covariates.
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c. LOS in quantiles:
In this model, LOS was divided into equal quantiles (5 classes) and these quantiles
were used as predictors.
d. LOS as cubic splines:
A cubic spline curve is a piecewise cubic curve with continuous second derivative. In
our analysis we used a restricted cubic spline with 4 knots. The restriction forces the
cubic spline to be linear at the two tails.96,97
iii. Medical diagnostic codes assigned during the initial hospital stay:
Medical diagnostic codes assigned to the infants at birth which are described in
Table 7 were also considered as severity measures of NOWS. While these conditions are
common in infants with NOWS, in the analysis we assumed that the presence of the
diagnostic codes would mean that these symptoms were serious enough to warrant
assigning of these specific diagnosis codes in the patients chart summary.
3.6.3 Outcomes
Outcomes from Aim 1 were used as the outcome of interest in Aim 2 as the scope
of this aim was also to assess post-discharge health care utilization. Time-to-event for the
first hospitalization and emergency department visit were not considered as outcomes of
interest for this Aim because of the limited sample size in the NOWS group and the small
number of events in the group.
3.6.4 Covariates
The covariates described in Aim 1 were used to obtain adjusted estimates in the
second Aim. Prematurity, jaundice, sepsis, and use of antibiotics were other medical
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covariates that were examined in the analysis. We used the sex of the infant, type of
insurance, race, hospital location (urban or rural), hospital census division, and bed size as
covariates in multivariable analyses.
3.7 Sensitivity analyses
3.7.1 Examination of the effect of LOS as a selection criterion on post-discharge
healthcare utilization.
We excluded late preterm infants whose LOS was less than 3 days to make the
study group comparable to the NOWS group. We evaluated the post-discharge health care
utilization across these two group after the restriction to assess if the differences in postdischarge health care utilization were a result of the difference in the exclusionary criteria.
3.7.2 Assessment of the difference in rates of pharmacological treatment of NOWS across
different hospitals and its impact on post-discharge health care utilization.
We created a binary variable to indicate if an infant was born in a hospital where
less than 25% of infants with NOWS received pharmacological treatment for their
condition. First, we evaluated the differences in post-discharge health care rate in NOWS
group based on the pharmacological treatment rates in the hospitals. We then excluded the
infants who were treated in hospitals where pharmaceutical treatment of NOWS was less
than 25% and compared post-discharge health care utilization in this restricted group with
the control groups. Lastly, we compared the association between pharmacological
treatment of NOWS and post-discharge health care utilization stratified by the
aforementioned hospital groups.
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3.7.3 Propensity score analysis for pharmacological management of NOWS.
A propensity score analysis was performed to account for the unmeasured
confounding related to pharmacological treatment of NOWS. Propensity score was
calculated for pharmacological treatment for NOWS using the following variables: sex of
the infant, cubic form of LOS, prematurity, respiratory conditions, feeding difficulties,
jaundice, sepsis, use of benzodiazepines, and use of antibiotics. The balancing property
was satisfied with 10 blocks where the mean propensity score in each block was not
statistically significant in the pharmacological treatment for NOWS vs. no
pharmacological treatment for NOWS groups. The propensity score was used in a linear
fixed effects model along with a binary variable for pharmacological treatment for NOWS
to predict post-discharge health care utilization (any composite visit, any 30-day composite
visit).
3.7.4 Principal component analysis for NOWS severity factors.
To account for the multiple factors related to severity of NOWS, many of which
were correlated, we used principal component analysis method. Principal components were
derived using the following set of NOWS severity related variables: pharmacological
management of NOWS, LOS, respiratory conditions, feeding difficulties, and use of
benzodiazepines. Eigen-value >1 was used as a criterion to select components.98 These
components were used as linear predictors to assess post-discharge healthcare utilization
(any composite visit, any 30-day composite visit).

51

3.8 Statistical Analyses
Baseline characteristics of the study population were presented as means for
continuous variables, whereas, percentages were used for categorical variables. We used
analysis of variance (ANOVA) to assess differences between the baseline characteristics
(continuous variables) among the three study groups. For categorical variables, we utilized
chi-square test to assess the independence of baseline characteristics across study groups.
Statistical models for each of the Specific Aims were based on the type of outcome
variable. For binary outcome variables, we utilized a logistic regression model. The
primary predictor for the Specific Aim 1 consisted of the study group, whereas for the
Specific Aim 2 the primary predictors were the severity measures for NOWS. First, we
used a simple unadjusted binary logistic regression to quantify the association between the
predictor variables and the outcome (Model 1). In the second step, a logistic regression
model that included all the possible demographic covariates described previously along
with the primary independent variable was fitted (Model 2). This step provided an adjusted
odds ratio for the association between the predictor and the outcome variables. Finally, in
the third step, we added the medical condition as confounders (Model 3).
Post-discharge health care utilization could be triggered by a variety of different
factors. Previous studies have reported that factors, such as infant sex, race, and type of
insurance (proxy for socio–economic condition), are possible predisposing factors that
could affect hospital readmissions or emergency department visits in infants.99,100
Furthermore, type of hospital, variation in health care utilization across regions and effect
of policy changes across an extended period of time could also potentially affect the rates
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of post-discharge health care utilization. Model 2 which incorporated these patient specific
and hospital related variable was intended to control for these effects.
Model 3 was used to incorporate medical diagnoses present at birth as possible
confounders which could affect post-discharge health care utilization in infants. Studies
have shown that presence of respiratory problems, jaundice, infection, and feeding
difficulties are associated with considerable risk to the infant at birth and could lead to
higher post-discharge health care utilization.101,102 These factors were included in the 3rd
model as we anticipated that they could potentially cause an over adjustment as these
conditions are very common in NOWS and late preterm infants. In addition, previous
studies have incorporated these covariates in their regression models assessing postdischarge health care utilization,36 thereby providing a priori framework for inclusion of
these covariates in the regression models.
Area under the receiver operating characteristic curve (AUROC) was used to assess
the predictive ability of the logistic regression models. The AUROC measures the ability
of the model to correctly classify the outcome (post-discharge health care utilization) based
on the predictors included in the model. In a logistic regression model, AUROC of 0.5 or
50% means failed classification (no better than a flip of a coin) and AUROC of 1 or 100%
means perfect classification.
For Poisson regression models, we used Akaike Information Criterion (AIC)103 as
the measure for evaluation of relative quality of statistical models. AIC of a model is given
by the following:
AIC= 2k - 2ln(L)
Where, k= number of parameters or predictors
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L= maximum value of the likelihood function.
Given a set of regression models for an outcome, the model with the lowest AIC is
preferred. In our study, we present AIC as AIC/N, where N= number of observation to
compare the relative quality of Poisson regression models.

Statistical models:
The following equation represents the proposed logistic regression model (adjusted
model with all the covariates) for Aim 1:
𝑝
log (
) = β0 + β𝑥 I + β𝑧 Z
1−𝑝

Where, p = probability of outcome
Bx = categorical variable for study group
I = indicator variable representative of the categories of the study group
βzZ = represents the covariates in the model with their respective beta coefficients
The null hypothesis (H0) in the model is specified as below,
H0: βx = 0
i.e. there is no difference in the log-odds ratio of outcome in between the control group and
the exposed group.
The following equation represents the proposed logistic regression model (adjusted
model with all the covariates) for Aim 2:
log (

𝑝
) = β0 + β𝑥 X + β𝑧 Z
1−𝑝

Where, p= probability of outcome
X= Row vector consisting of all the primary independent variables
βx= corresponding beta coefficients for the primary independent variables
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βzZ = represents the covariates in the model with their respective beta coefficients
The null hypothesis (H0) in the model is specified as below,
H0: βx = 0
i.e. there is no effect of NOWS severity measures on post-discharge health care utilization.
For count based outcome variables we used Poisson regression models. In the first
step, a simple Poisson model with the count outcome variable and the primary predictor
variable was fitted. In the second step, a full Poisson model with all the demographic
covariates described previously was constructed. Finally, in the third step, a full Poisson
log-linear model along with medical conditions as additional confounders was fitted.
A simple Poisson model for Aim 1 is specified as the following:
𝑦

Pr[𝑌𝑖 = 𝑦𝑖 ] =

𝑒 𝜆𝑖 𝜆𝑖 𝑖
𝑦𝑖 !

, yi =0, 1, 2…

The log-linear specification of the model (adjusted model) is given by:
ln 𝜆 = β0 + β𝑥 I + β𝑧 Z
Where, λ = mean count of the outcome variable.
X = categorical variable for study group
I = indicator variable representative of the categories of the study group
βzZ = represents the covariates in the model with their respective beta coefficients
The null hypothesis (H0) in the model is specified as below,
H0: βx = 0
i.e. there is no difference in the log ratio of the mean number of outcomes in the control
groups to the exposed group (infants with NOWS) after controlling for other covariates.
The log-linear specification of the model (adjusted model) for Aim 2 is given by:
ln 𝜆 = β0 + β𝑥 X + β𝑧 Z
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Where, λ= mean count of outcome variable.
X= Row vector consisting of all the primary independent variables
βx= corresponding beta coefficients for the primary independent variables
βzZ = represents the covariates in the model with their respective beta coefficients
The null hypothesis (H0) in the model is specified as below,
H0: βx = 0
i.e. there is no effect of NOWS severity measures on outcomes during the one-year followup period post-discharge in infants with NOWS. The results of Poisson regression model
are shown as Incidence rate ratio (IRR) which is obtained by exponentiating the Poisson
regression coefficient.
One of the limitations of Poisson regression model is that it assumes the variance
of the outcome is equal to its mean (or expected value). Since the outcomes consisted of
high number of zero values we also constructed a Zero-inflated Poisson regression model
as a robustness check to the Poisson regression.
For time-to-event based analysis, we first we used a Kaplan-Meier estimator to
estimate the time-to-event (time to first health care utilization event in days).104 KaplanMeier plots for time to first rehospitalization and first emergency department visits across
the study groups were created. We then performed log-rank test of equality of time to event
function across study groups. Finally, Cox proportional-hazards regression models were
used to test the effect of NOWS on time to a hospital readmission or emergency department
visits in comparison to the control groups. The following equation represents the proposed
Cox proportional-hazards regression model (adjusted model with all the covariates for Aim
1.A:
ℎ(𝑡) = h0 (t) + exp(β𝑥 I + β𝑧 Z)
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Where, h(t) = hazard function at time t
h0(t) =baseline hazard
Bx = categorical variable for study group
I = indicator variable representative of the categories of the study group
βzZ = represents the covariates in the model with their respective beta coefficients
The null hypothesis (H0) in the model is specified as below,
H0: βx = 0
i.e. there is no difference in the log ratio of hazard function at time t in between the control
group and the exposed group.

Clustering to obtain robust standard errors:
Post-discharge care of an infant can take place at any health care centers in the
infants surrounding. However, only those encounters that take place at hospitals that utilize
CERNER EHRs will be recorded in the HF database. Let us assume that there is a mixture
of health care centers (based on the utilization of CERNER EHR) around an infant’s initial
treatment center (birthing hospital). Furthermore, that the mixture is random across all the
different health centers/hospitals where the infant was born/managed. Therefore, the
probability that an infant will seek care at a hospital or a health center that utilizes CERNER
EHR can be considered a random effect across the hospitals where the initial care takes
place. We used the clustered robust standard errors approach, where the observations were
clustered across the hospitals where the initial care was provided, to account for the
variability in the probability of access of care at a center that uses CERNER EHR.
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3.9 Power analysis
Aim 1: Power analysis for Aim 1 was based on the study conducted by Patrick et
al. where hospital readmission rates for infants with NOWS was evaluated using New York
Inpatient Database.36 The study reported that 30-day hospital readmission was
approximately 3% in infants with NOWS compared to approximately 1.9% in infants with
uncomplicated term births. Similarly, almost 7.7% of the infants born with NOWS had
one-year hospital readmissions compared to 4% in infants with uncomplicated term births.
Additionally, adjusted odds ratio (OR) for 30-day hospital readmissions for infants with
NOWS was estimated to be 2.49 (95% C.I.: 1.75-3.55) compared to infants who had
uncomplicated term births. While this study reported that the incidence of NOWS was
approximately 2 per 1000 births in 2009, we used a recent estimate of 6 per 1,000 births in
2013105 approximating the time period of our analysis.
For this calculation, the alpha value was set at 0.05 and sample size to achieve a
power of 0.8 to 0.85 and was calculated using G*Power software.106 We used a
dichotomous predictor (presence or absence of NOWS) based on the information available
for power calculation.
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Table 8: Power analysis for Aim 1
Model

Power

Aim

Prevalence P0

P1

of NOWSa

Measure of Total
associationb Sample
size

Logistic

.85

1.A

6

0.03

0.019

OR = 1.6

272,916

0.8

1.A

6

0.03

0.019

OR = 1.6

234,313

0.85

1.A

6

-

-

aOR = 2.5

55,052

0.8

1.A

6

-

-

aOR = 2.5

46,396

.85

1.B

6

0.077

0.04

OR = 2.0

54,033

0.8

1.B

6

0.077

0.04

OR = 2.0

46,048

regression
Logistic
regression
Logistic
regression
Logistic
regression
Logistic
regression
Logistic
regression
a

per 1000 births

b

OR = odds ratio, aOR = adjusted odds ratio
Based on the power analysis for Aim 1, with the conservative estimates (OR=1.6

and power =0.85) we would need a sample size of approximately 270,000 total births which
reflects at least 1600 encounters of NOWS based on prevalence rates of 6 per 1000 births
(Table 8). The constraint in this estimate is primarily the number of births with a diagnosis
of NOWS in comparison to total birth. Additionally, if we used a stronger effect size of
OR=2.5 and 80% power, then a total sample size of approximately 46,000 will be sufficient
for our study. During preliminary analysis we were able to identify approximately 3,000
encounters with diagnosis of NOWS/NAS. Based on these calculation, we achieved
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required sample size to be able to detect the effect of diagnosis of NOWS on long-term
health care utilization.
Aim 2: Research on the association between severity of NOWS and long-term
health care utilization is lacking. Hence, we utilized the concept of event per variable
outlined by Peduzzi et al. to estimate the sample size for Aim 2.107 Based on Peduzzi et
al.’s work, the sample size for a logistic regression model can be estimated through the
equation below:
N = 10*K / P
where, N = total sample size
K = number of covariates
P = proportion of events in the population
Assuming that we have a minimum of 5 covariates in the model, and that the
probability of 30-day hospital readmission in infants with NOWS is 0.0336, then the sample
size required will be approximately 1,666. Similarly, using the rates of hospital readmission
during the one-year follow-up, which is 0.077, the estimated sample size required would
be approximately 650. Since our estimated sample size was approximately 3,000, our study
was powered sufficiently to detect any effect of NOWS severity measures of postdischarge health care utilization.
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CHAPTER 4: RESULTS
In this section we describe the geographic and temporal trends in the incidence of
NOWS. It is followed by the results for Aim 1 and Aim 2. We conclude the section by
presenting the results of sensitivity analyses for Aim 1 and Aim 2.
4.1 Description of sample selection across the study groups:
A total of 4,874 encounters related to NOWS (study period Jan 1, 2011 – Sep 30,
2016) were identified from the HF database. Of this group, 3,526 were selected for
inclusion in the final study cohort after the application of exclusion criteria and removal of
duplicates. For the late preterm group, 31,260 infants were identified from the HF database,
and 24,472 records were included in the study after the application of exclusion criteria
and removal of duplicates. For the uncomplicated birth group, 433,368 infants were
initially identified during the same study period from the HF database. Of this group,
355,875 infants were retained after duplicates were removed and exclusion criteria was
applied. A random sample of 25% of this group was selected for the final study. Sample
section/attrition flowchart for the study is presented in Figures 5, 6, and 7.
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Figure 5: Sample selection flowchart for the NOWS group
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Figure 6: Sample selection flowchart for the late preterm group
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Figure 7: Sample selection flowchart for the uncomplicated birth group
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4.1 Geographic and temporal trends in incidence of NOWS
The incidence rate of NOWS in infants born into health systems that utilized
CERNER data systems was approximately 5.9 per 1000 births in the year 2011. There was
a high degree of variability in the incidence of NOWS across different census divisions. In
census division 1 (New England) and 3 (East North Central) the incidence rates of NOWS
was over 10 per 1000 births, whereas in census division 4 (West North Central), 5 (South
Atlantic), 7 (West South Central), and 9 (Pacific) it was lower than 3 per 1000 births (Table
9). There was an upward trend in the incidence of NOWS between 2011 and 2016. The
rates increased from 5.9 per 1000 births in 2011 to 13.1 per 1000 births in 2016 – a 120%
increase in 5 years. The variability in incidence of NOWS across census divisions persisted,
with a greater number of census divisions reaching incidence rates of more than 10 per
1000 births between 2011 and 2016. We also observed a substantial increase in NOWS in
Census Division 1 where the incidence rate peaked at approximately 50 per 1000 births in
the year 2014.
While the incidence of NOWS consistently showed an upward trend, the incidence
rate of late-preterm birth during the study period remained fairly constant at 63 per 1000
births until 2015 and then increasing to approximately 72.5 per 1000 births in the year
2016. This represents a 20% increase between 2011 and 2016.

65

Table 9: Incidence rates of NOWS and late preterm per 1000 total live births in infants born into centers that utilized CERNER
EHR (Years: 2011-2016)
Census
division
1
2
3
4
5
6
7
8
9
Total

2011
NOWS
Late
preterm
15.5
70.8
8.9
51.6
10.4
76.9
2.3
34.8
2.0
58.7
5.9
81.8
0.7
72.9
4.3
45.6
2.4
65.0
60.6
5.9

2012
NOWS
Late
preterm
22.3
81.3
6.1
46.6
6.6
106.7
4.4
41.7
0.9
84.2
7.9
84.8
3.9
72.8
6.3
45.4
2.8
71.0
65.0
7.4

2013
NOWS
Late
preterm
32.4
78.0
4.4
26.2
5.2
94.2
9.3
66.7
1.8
75.5
5.7
86.9
3.7
84.8
15.6
82.5
1.6
71.8
63.7
8.0
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2014
NOWS
Late
preterm
49.7
57.0
7.6
30.0
4.5
98.4
14.7
76.5
2.4
78.2
8.6
73.6
5.5
74.5
18.3
77.8
2.5
67.4
63.0
11.3

2015
NOWS
Late
preterm
21.8
40.1
8.5
37.1
4.8
100.1
14.1
71.3
5.0
68.3
14.1
81.2
4.9
68.0
17.0
79.0
2.2
73.3
64.9
10.3

2016
NOWS
Late
preterm
17.9
32.7
20.0
66.7
6.4
81.4
3.5
82.1
18.5
43.6
18.7
82.6
6.5
75.7
16.5
73.1
6.5
68.4
72.5
13.1

Table 10 presents the baseline characteristics of the study groups. Statistical
significant differences (p<0.05) were observed across sex, race, type of insurance, census
region of birth, the urban-rural status of the birthing center, and the hospital size (based on
the number of beds). Compared to the uncomplicated birth group, NOWS and late preterm
groups had significantly higher proportion of males (52.5% and 53.7%, respectively vs
50.6% in uncomplicated birth group). Almost 80% of the infants diagnosed with NOWS
were Caucasian compared to 54.0% in the late preterm group, and 57.0% in the
uncomplicated birth group. About 69% of the birth-related encounters in the NOWS group
were covered by Medicaid; 12% were covered by commercial insurance, and the remaining
by other types of insurance (included self-pay, other non-governmental, military
dependent, not-reported etc.). In the late preterm group, only 43.8% of birth-related
encounters were covered by Medicaid, 18.9% by commercial insurance, and the remaining
by other forms of coverage. Commercial insurance covered 44% of the initial birth-related
encounters in the uncomplicated birth group, Medicaid covered 34.3%, and 21.5% was
covered by other forms of coverage. In the NOWS group, 64% of the births were recorded
in hospitals with greater than 300 beds, 29% in hospitals with 100 to 299 beds, and only
7.3% in hospitals with less than 100 beds. Late-preterm and uncomplicated births had fairly
similar distribution to each other in regards to the size of the hospital. Fifty percent of late
preterm and uncomplicated births were recorded in hospitals with greater than 300 beds,
37% in hospitals with 100 to 299 beds, and 13% in hospitals with less than 100 beds.
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Table 10: Description of demographic characteristics and patient care setting by study
group
Variable

NOWS
(n=3,526)

Late
preterm
birth
(n=24,474)

Uncomplicated
births*
(n=88,452)

Sex
Male
52.5%
53.7%
50.6%
Female
47.5%
46.3%
49.4%
Race
Caucasian
79.4%
54.0%
57.0%
African American
5.9%
18.8%
14.1%
Hispanic
0.8%
2.7%
2.8%
Native American
2.7%
2.2%
1.2%
Other
11.3%
22.4%
24.9%
Insurance Type
Medicaid/Medicaid MC
69.1%
43.8%
34.3%
Commercial
11.9%
37.3%
44.4%
Other
18.9%
18.9%
21.4%
Census region
Midwest
16.9%
25.2%
22.9%
Northeast
44.2%
22.6%
33.1%
South
23.5%
34.2%
28.1%
West
15.4%
18.0%
16.0%
Rural/Urban Status
Rural
15.2%
18.2%
17.0%
Urban
84.8%
81.8%
83.0%
Bed size range
Less than 100
7.4%
13.5%
13.3%
100-299
28.5%
36.6%
37.6%
Greater than 300
64.2%
50.0%
49.1%
Year
2011
9.4%
13.9%
15.0%
2012
11.9%
15.2%
15.2%
2013
15.3%
17.5%
18.0%
2014
23.3%
18.8%
19.5%
2015
20.4%
18.5%
18.4%
2016
19.3%
16.2%
14.0%
*Uncomplicated births are 25% sample of the uncomplicated births in each year.
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pvalue

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

-

There were 782 unique hospital IDs in the HF database. After selection of the cohort
for our study, we identified 186 unique hospital IDs which represented a total of 116,452
births that were included in the study. In Table 11, we present the distribution of these
hospitals based on the U.S. census divisions.
Table 11: Distribution of hospitals (included in our final analysis) that utilize CERNER
EHR systems across U.S. census divisions
Census divisions

Hospitals/health centers

1 (New England)

9

2 (Mid-Atlantic)

25

3 (East North Central)

22

4 (West North Central)

23

5 (South Atlantic)

11

6 (East South Central)

37

7 (West South Central)

17

8 (Mountain)

24

9 (Pacific)

18

Total

186

In Table 12, we describe the characteristics of the primary medical encounter by
study groups. There was a significant difference in the average LOS across the study groups
(p<0.001). The average LOS was 14.9 days (SD=11.5) in the NOWS group, 8.6 days
(SD=8.7) in the late preterm group, and 2.1 days (SD=0.8) in the uncomplicated birth group
(p<0.001). The median total charges (adjusted to 2016 U.S. dollars) in the NOWS group
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was $24,944, $15,970 in the late preterm group, and $3,129 in the uncomplicated birth
group (p<0.001).
Respiratory problems were common in both the NOWS and late preterm groups.
Approximately 20% of the infants in the NOWS group and 34% in the late preterm group
had respiratory problems (Respiratory distress syndrome, transient tachypnea of newborn,
other respiratory condition). Major differences between these groups were seen in the
diagnosis of respiratory distress syndrome (NOWS: 4.7% vs. late preterm: 12.9%,
p<0.001) and other specified respiratory conditions (NOWS: 7.5% vs. late preterm: 13.8%,
p<0.001). Respiratory problems in the uncomplicated birth group was less than 3%. In the
NOWS group, 1.2% of the infants had a diagnostic code for convulsion compared to 0.4%
in the late preterm group, and 0.1% in the uncomplicated birth group (p<0.001). Other
commonly present diagnostic codes in the NOWS and the late preterm group were feeding
difficulties (NOWS: 18.4% vs. late preterm: 22.0%, p<0.001), jaundice (NOWS 35.6% vs.
late preterm 47.4%, p<0.001), and sepsis (NOWS 4.6% vs. late preterm 7.5%, p<0.001).
Besides jaundice (uncomplicated birth: 10.9%), these conditions were rare in the
uncomplicated birth group (less than 2%).
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Table 12: Description of the primary medical encounter by study groups
NOWS
(n=3,526)

LOS (days)
Total Charges in dollars*
(median)

14.9 (11.5)
$24,944

Late
Uncomplicated
ppreterm
births*
value
birth
(n=88,452)
(n=24,474)
Mean (SD)
8.6 (8.7)
2.1 (0.8)
<0.001
$15,970
$3,129
<0.001
%

Gestational age at delivery
33 weeks to less than 37
weeks
Any respiratory problems
Type of respiratory
problems
Respiratory distress
syndrome
Transient tachypnea of
newborn
Respiratory condition of
newborn (unspecified)
Other specified respiratory
condition
Convulsions
Feeding difficulties
Jaundice
Sepsis

<0.001
14.7%

100%

0%

20.8%

34.0%

2.6%

4.8%

12.9%

0.2%

11.3%

11.8%

1.5%

0.8%

1.5%

0.1%

7.5%

13.8%

1.1%

1.2%
18.4%
35.6%
4.6%

0.4%
22.0%
47.4%
7.5%

0.1%
1.0%
10.9%
0.4%

<0.001

<0.001
<0.001
<0.001
<0.001

4.2: Results for Specific Aim 1
Specific Aim 1 examined post-discharge healthcare utilization during the one-year
follow up period in the NOWS group compared to the late preterm, and uncomplicated
birth groups. Post-discharge healthcare utilization was measured by emergency department
visits, hospital readmissions (inpatient stay), and outpatients visits.
Table 13 shows the rates of post-discharge healthcare utilization during the oneyear follow-up period in the three study groups. The NOWS and late preterm groups
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showed similar post-discharge health care utilization, such as rates of rehospitalization
(~4%) and rates of emergency department visits (~7.5%). In comparison, rehospitalization
and emergency department visits were lower in the uncomplicated birth group (1.6%, and
6.1% respectively). The mean number of outpatient visit per person was significantly
higher in the late preterm group (0.047) compared to NOWS (0.037) and uncomplicated
birth (0.038) groups (p<0.001).
We observed differences (range: any composite visit: 8.5%-13.2%; any 30-day
composite visit: 2.1%-6.7%) in the post-discharge health care utilization based on the year
of discharge (Table 14). Highest rate of post-discharge visits (any composite or any 30-day
composite visits) were observed in the year 2013. In comparison the rate of post-discharge
health care utilization in the late preterm and uncomplicated birth groups remained fairly
constant.
The association between the study groups and hospital readmissions during the oneyear follow-up period is shown in Table 15. In the unadjusted model, we observed
significantly higher odds of hospital readmission in the NOWS group (OR: 2.5, 95% C.I.:
2.0-3.3) compared to controls (uncomplicated birth). In model 2 (adjusted for sex, race,
insurance type, urban-rural status, census region, hospital size and year of discharge), the
results still showed a significant association between NOWS and hospital readmission (OR
2.0, 95% C.I.: 1.4-2.7) when compared to uncomplicated birth group. In model 3
(additional adjustment for respiratory conditions, feeding problems, jaundice, sepsis, and
convulsions) the odds of rehospitalization in the follow-up period in the NOWS group was
1.7 times the odds in the uncomplicated birth group (95%CI: 1.4-1.9). Similarly, across all
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the models, infants who had late preterm births showed higher odds of rehospitalization
during the one-year follow-up period when compared to the uncomplicated birth group.
There was a significant association between NOWS and 30-day rehospitalization
(OR: 2.7, 95% C.I.: 1.9-3.8). The association persisted after the adjustment for
demographic and hospital-related factors in model 2 (OR: 2.1, 95% C.I.: 1.4-3.2) and
medical conditions in model 3 (OR: 1.9, 95% C.I.: 1.3-2.6). Similarly, across all the
models, infants who had late preterm births also showed higher odds of 30-day
rehospitalization compared to uncomplicated birth group.
In the sub-group analysis, we compared the rates of rehospitalization in the NOWS
group to the late preterm group. After adjustment of demographics and medical conditions,
the odds of any rehospitalization was lower in the NOWS group (OR: 0.8, 95% C.I.: 0.60.98) compared to the late preterm group. However, there was no difference in 30-day
rehospitalization across these groups (NOWS vs. late preterm group).
Table 16 describes the association between emergency department visits and study
groups during the one-year follow-up period. In the unadjusted analysis, we observed that
infants in the NOWS group had higher odds of emergency department visits compared to
the uncomplicated birth group in the one-year follow-up period (OR: 1.5, 95% C.I.: 1.11.9). The results were not statistically significant after adjustment of demographic factors
in model 2, and after the addition of medical conditions in model 3. In the unadjusted
model, the NOWS group had higher odds of 30-day emergency department visits compared
to the uncomplicated birth group (OR: 1.5, 95% C.I.: 1.2-1.9). After adjustments in model
2 and 3, the association was marginally significant (Model 3, OR: 1.3, 95% C.I.: 1.0-1.6).
However, compared to the uncomplicated birth group, late preterm group had significantly
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higher odds of any emergency department visit and 30-day emergency department visit in
all the unadjusted and adjusted models. In the sub-group analysis, we observed no
difference in the rates of any emergency department visits (one-year period) or 30-day
emergency department visits across all the unadjusted and adjusted logistic regression
models between the NOWS group and the late preterm group.
Table 17 describes the differences in composite healthcare utilization (i.e., any
emergency department visit or rehospitalization), during the one-year follow-up period
between the study groups. In the unadjusted analysis, there were higher odds of composite
healthcare utilization in the NOWS group (OR: 1.5, 95% C.I.: 1.4-1.7) compared to the
uncomplicated birth group. However, after adjustments, these associations were not
statistically significant.
We found higher odds of 30-day composite health care utilization in the NOWS
group compared to the uncomplicated birth group across all unadjusted and adjusted
logistic regression models. The unadjusted model showed that the odds of composite
healthcare utilization in the NOWS group was 1.9 times the odds in the uncomplicated
birth group (95% C.I.: 1.6-2.2). After adjusting for demographics and hospital
characteristics in model 2 the odds ratio was 1.5 (95% C.I.: 1.3-1.8). In model 3, the odds
ratio was 1.4 (95% C.I.: 1.2-1.6).
We found similar association between late preterm birth and composite measures
of healthcare utilization. The late preterm group had significantly higher odds of a hospital
or emergency room visit, or any 30-day composite visit, compared to the uncomplicated
birth group across all unadjusted and adjusted models. In the sub-group analysis, NOWS
group had lower odds of any composite visit, compared to the late preterm group, after
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adjustment of demographics and medical characteristics (Model 3, OR: 0.8, 95% C.I.: 0.60.98). However, there was no difference in any 30-day composite health care utilization
across the two groups.
The results of analysis of differences in post-discharge outpatient visits across the
study groups is presented in Table 18. In the unadjusted and adjusted logistic regression
models, there were no differences in the odds of outpatient visit across the study groups.
Similarly, in the sub-group analysis, there were no differences in post-discharge outpatient
visit between the NOWS group and the late preterm group.
Model metrics-AUROC for logistic regression models
The unadjusted logistic regression model with the study group as the predictor had
an AUROC of 60% or lower across the outcome measures evaluated in the study. Addition
of infant demographic covariates in model 2 showed considerable improvement in AUROC
(from 60% to approximately 68%). However, addition of other medical condition related
covariates in model 3 did not produce major improvements in the AUROC (approximate
improvement in AUROC 1.5%) These changes in AUROC showed that adding covariates
related to medical condition over the demographic characteristics did not provide
additional information in predicting post-discharge health care utilization. This is likely
because these conditions were common in the late preterm and NOWS group possibly
leading to more collinearity rather than explaining the variability of the outcomes.
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Table 13: Post-discharge healthcare utilization by study groups
Variable

Rehospitalization
Mean rehospitalization
Any rehospitalization
Any 30-day
rehospitalization
Emergency Department
Mean emergency
department visit
Any emergency
department visit
Any 30-day emergency
department visit
Any (Rehospitalization
or Emergency
Department)
Total mean visits
(Rehospitalization and
Emergency Department)
Any visit
(Rehospitalization and
Emergency Department)
Any 30-day visit
(Rehospitalization and
Emergency Department)
Outpatient visit
Mean outpatient visit
Any outpatient

NOWS
(n=3,526)

Late
preterm
birth
(n=24,474)

Uncomplicated
births
(n=88,452)

pvalue

0.042
3.8%
2.4%

0.049
4.3%
2.9%

0.0166
1.6%
0.9%

<0.001
<0.001
<0.001

0.114

0.114

0.86

<0.001

7.5%

7.6%

6.1%

<0.001

2.0%

1.8%

1.6%

<0.001

0.156

0.163

0.102

<0.001

10.4%

11.1%

7.3%

<0.001

4.3%

4.5%

2.4%

<0.001

0.371
12.4%

0.470
16.2%

0.376.
14.9%

<0.001
<0.001
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Table 14: Yearly variation in post-discharge health care utilization (Composite measures)
across study groups
Year

NOWS
(n=3,526)

2011
2012
2013
2014
2015
2016

8.5%
12.4%
13.2%
8.5%
10.8%
9.7%

Any e visit
Late preterm
birth
(n=24,474)
10.7%
12.1%
11.4%
10.1%
11.6%
10.3%

Uncomplicated
births
(n=88,452)
7.3%
8.4%
7.6%
7.7%
7.0%
5.5%

Any 30-day visit
Year
2011
2012
2013
2014
2015
2016

2.1%
5.7%
6.7%
3.0%
3.3%
4.9%

3.9%
5.1%
4.7%
3.9%
4.8%
4.8%
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1.9%
2.4%
2.5%
2.5%
2.4%
2.9%

Table 15: Logistic regression model for rehospitalization during one-year follow-up period

Any rehospitalization
Uncomplicated births
(Ref) vs. NOWS
Uncomplicated births
(Ref) vs. Late preterm
births
AUROC
Late preterm births
(Ref) vs. NOWS
AUROC

Uncomplicated births
(Ref) vs. NOWS
Uncomplicated births
(Ref) vs. Late preterm
births
AUROC

Model 1

Model 2
Odds Ratio (95% C.I.)

Model 3

2.5 (2.0-3.3)

2.0 (1.4-2.7)

1.7 (1.3-2.2)

2.9 (2.3-3.6)

2.7 (2.2-3.3)

2.2 (1.8-2.7)

61.5%
68.5%
Sub-group analysis
0.9 (0.7-1.1)
0.7 (0.6-0.9)
50.7%

62.4%

69.0%
0.8 (0.6-0.98)
63.3%

30-day rehospitalization
2.7 (1.9-3.8)
2.1 (1.4-3.2)

1.9 (1.3-2.6)

3.3 (2.6-4.3)

2.6 (2.0-3.3)

3.1 (2.4-4.0)

63.0%
69.0%
Sub-group analysis
0.8 (0.6-1.0)
0.7 (0.5-1.0)

69.6%

Late preterm births
0.7 (0.5-1.1)
(Ref) vs. NOWS
AUROC
51.1%
61.9%
62.2%
Ref: Reference
AUROC: Area under the receiver operating characteristic curve (for the logistic regression
models)
Model 1: Unadjusted model
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division,
hospital size, year of discharge
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and
convulsions
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Table 16: Logistic regression model for emergency department visits during one-year
follow-up period
Model 1

Uncomplicated births
(Ref) vs. NOWS
Uncomplicated births
(Ref) vs. Late preterm
births
AUROC
Late preterm births
(Ref) vs. NOWS
AUROC
Uncomplicated births
(Ref) vs. NOWS
Uncomplicated births
(Ref) vs. Late preterm
births
AUROC

Model 2
Odds Ratio (95% C.I.)
Any emergency department visit
1.5 (1.1-1.9)
1.1 (0.9-1.3)
1.6 (1.4-1.9)

1.4 (1.3-1.6)

52.3%
67.7%
Sub-group analysis
1.0 (0.7-1.4)
0.8 (0.7-1.1)
50.1%
65.0%
30-day emergency department visit
1.8 (1.7-2.3)
1.4 (1.1-1.8)
1.9 (1.6-2.3)

1.7 (1.4-2.0)

51.2%
66.5%
Sub-group analysis
1.2 (0.8-1.6)
1.1 (0.9-1.5)

Model 3

1.0 (0.8-1.2)
1.2 (1.2 -1.5)

67.7%
0.8 (0.6-1.1)
65.0%
1.3 (1.0-1.6)
1.6 (1.3-1.8)

66.5%

Late preterm births
1.1 (0.9-1.5)
(Ref) vs. NOWS
AUROC
50.9%
64.9%
65.1%
Ref: Reference
AUROC: Area under the receiver operating characteristic curve (for the logistic regression
models)
Model 1: Unadjusted model
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division,
hospital size, year of discharge
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and
convulsions
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Table 17: Logistic regression model for any emergency department visit or
rehospitalization during one-year follow-up period
Model 1

Model 2
Model 3
Odds Ratio (95% C.I.)
Any visit (emergency department or rehospitalization)
Uncomplicated births
1.5 (1.4-1.7)
1.1 (1.0-1.3)
1.1 (0.9-1.2)
(Ref) vs. NOWS
Uncomplicated births
1.6 (1.6-1.7)
1.5 (1.4-1.6)
1.4 (1.3-1.4)
(Ref) vs. Late preterm
births
AUROC
54.6%
66.4%
66.5%
Sub-group analysis
Late preterm births
0.9 (0.7-1.2)
0.8 (0.6-0.96)
0.8 (0.6-0.98)
(Ref) vs. NOWS
AUROC
50.4%
62.7%
62.9%
Any 30-day visit (emergency department or rehospitalization)
Uncomplicated births
1.9 (1.6-2.2)
1.5 (1.3-1.8)
1.4 (1.2-1.6)
(Ref) vs. NOWS
Uncomplicated births
2.0 (1.9-2.2)
1.9 (1.7-2.0)
1.7 (1.5-1.8)
(Ref) vs. Late preterm
births
AUROC
56.7%
64.9%
65.1%
Sub-group analysis
Late preterm births
0.9 (0.7-1.2)
0.9 (0.7-1.1)
0.9 (0.7-1.2)
(Ref) vs. NOWS
AUROC
50.4%
59.9%
60.0%
Ref: Reference
AUROC: Area under the receiver operating characteristic curve (for the logistic regression
models)
Model 1: Unadjusted model
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division,
hospital size, year of discharge
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and
convulsions
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Table 18: Logistic regression model for any outpatient visit during one-year follow-up
period
Model 1
Uncomplicated births
(Ref) vs. NOWS
Uncomplicated births
(Ref) vs. Late preterm
births
AUROC

0.8 (0.4-1.5)

Model 2
Odds Ratio (95% C.I.)
0.9 (0.6-1.5)

0.9 (0.6-1.4)

1.1 (0.9-1.4)

1.0 (0.8-1.2)

1.0 (0.9-1.2)

51.2%
69.7%
Sub-group analysis
0.7 (0.4-1.2)
0.8 (0.6-1.2)

Model 3

69.8%

Late preterm births
0.8 (0.6-1.2)
(Ref) vs. NOWS
AUROC
51.6%
67.9%
68.2%
Ref: Reference
AUROC: Area under the receiver operating characteristic curve (for the logistic regression
models)
Model 1: Unadjusted model
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division,
hospital size, year of discharge
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and
convulsions
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Tables 19 and 20 present the comparison of the incidence rates of post-discharge
health care utilization among the study groups, using Poisson and Zero-inflated Poisson
regression models. The incidence rates of any composite visit and rehospitalization were
significantly higher in the NOWS group compared to the uncomplicated birth group across
all unadjusted and adjusted models (any composite visit Model 3: IRR: 1.4, 95% C.I.: 1.21.6 and rehospitalization, Model 3: IRR: 2.1, 95% C.I.: 1.6-2.7). For any emergency
department visit, the association was marginally significant across all three statistical
models (Model 3, IRR: 1.3, 95% C.I.: 1.02-1.6) between NOWS group and uncomplicated
birth group. No differences in the rates of outpatient visits were observed across the study
groups.
To account for the high number of zero values in the counts of healthcare utilization
visits (no use), we used the Zero-inflated Poisson regression model as a robustness check
for our previous analysis. The incidence rate of any composite visit in the NOWS group
was not significantly different than that in the uncomplicated birth group (Model 3, IRR:
1.1, 95% C.I.: 0.95-1.3). However, the incidence rate of rehospitalization in the NOWS
group was statistically significant (Model 3, IRR: 1.8, 95% C.I.: 1.4-2.3) when compared
to the uncomplicated birth group. We did not observe significant differences in the rates of
emergency department visit or outpatient visit in the NOWS group compared to the
uncomplicated birth groups.
In the sub-group analysis (Table 20), there were no differences in any composite
visit, emergency department or outpatient visit, in the NOWS group vs. the late preterm
group. The rates of rehospitalization, however, were significantly lower in the NOWS
group (Model 3, IRR: 0.8, 95% C.I.: 0.6-0.9) compared to the late preterm group.
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Model metrics-AIC/N for Poisson regression models
The unadjusted Poisson regression model with the study group as the predictor and
any composite visit as outcome had an AIC/N value of 0.798 (lower scores denote better
fit). Addition of covariates, such as sex, race, insurance type, urban-rural status, year,
hospital id, and census division, in model 2 showed improvement in AIC to 0.777.
However, addition of other medical condition related covariate in model 3 did not produce
any changes in AIC/N values. Similarly, the AIC/N values for any rehospitalization
improved to 0.226 from 0.224 after addition of demographic and hospital characteristics
related covariates. There was no improvement in AIC/N in Model 3. The results for the
Poisson model for emergency department visits and outpatient visits also showed
consistent pattern of improvement in model 2 after addition of demographics and hospital
characteristics but no change with the addition of other covariates in Model 3.
Similarly, in the Zero-inflated Poisson regression models, consistent improvement
in the model fit was observed after the addition of demographic and hospital related
covariates in Model 2 over Model 1. There was limited or almost no improvement in model
fit in model 3.
These changes in the AIC/N showed that medical covariates (Model 3) did not add
additional information beyond what was provided by demographic characteristics in model
2. As explained previously, this is likely because these conditions were most common in
the late preterm and NOWS group possibly leading to more collinearity rather than
explaining the variability of the outcomes.
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Table 19: Poisson and Zero-inflated Poisson model for post-discharge health care
utilization by study groups during one-year follow-up period
Any visit

Model 1
Uncomplicated
births (Ref) vs.
NOWS
Uncomplicated
births (Ref) vs. Late
preterm births
AIC/N
Model 2
Uncomplicated
births (Ref) vs.
NOWS
Uncomplicated
births (Ref) vs. Late
preterm births
AIC/N
Model 3
Uncomplicated
births (Ref) vs.
NOWS
Uncomplicated
births (Ref) vs. Late
preterm births
AIC/N
Model 1
Uncomplicated
births (Ref) vs.
NOWS
Uncomplicated
births (Ref) vs. Late
preterm births
AIC/N
Model 2
Uncomplicated
births (Ref) vs.
NOWS

Rehospitalization

Emergency
department
IRR (95% C.I.)
Poisson model
1.5 (1.2-2.0)
2.5 (2.0-3.2)
1.3 (0.9-1.9)

Outpatient
visits

1.0 (0.5-2.0)

1.6 (1.4-1.9)

3.0 (2.3-3.7)

1.3 (1.1-1.6)

1.2 (1.031.5)

0.798
1.5 (1.2-1.8)

0.226
2.4 (1.8-3.1)

0.679
1.3 (1.041.6)

2.188
1.0 (0.5-2.0)

1.5 (1.3-1.7)

2.9 (2.3-3.6)

1.2 (1.1-1.4)

1.1 (0.9-1.4)

0.777
1.4 (1.2-1.6)

0.224
2.1 (1.6-2.7)

0.658
1.3 (1.021.6)

1.989
1.0 (0.5-2.0)

1.4 (1.2-1.6)

2.4 (1.9-3.0)

1.2 (1.0-1.3)

1.1 (0.9-1.3)

0.777
0.224
0.658
Zero inflated Poisson model
1.2 (0.9-1.5)
2.2 (1.8-2.6)
1.0 (0.8-1.4)

1.987
-1.0 (0.5-2.1)

1.3 (1.2-1.5)

2.8 (2.2-3.5)

1.2 (1.1-1.3)

1.2 (1.031.5)

0.702
1.2 (1.1-1.3)

0.220
2.0 (1.6-2.6)

0.583
1.0 (0.8-1.3)

1.354
1.1 (0.7-1.7)
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Uncomplicated
1.4 (1.3-1.4)
2.8 (2.2-3.4)
1.2 (1.1-1.3) 1.2 (1.0-1.4)
births (Ref) vs. Late
preterm births
AIC/N
0.693
0.219
0.576
1.303
Model 3
Uncomplicated
1.1 (0.951.8 (1.4-2.3)
1.0 (0.8-1.3) 1.1 (0.7-1.6)
births (Ref) vs.
1.3)
NOWS
Uncomplicated
1.3 (1.2-1.4)
2.4 (1.9-2.9)
1.2 (1.0-1.3) 1.1 (1.0-1.3)
births (Ref) vs. Late
preterm births
AIC/N
0.693
0.218
0.575
1.303
IRR: Incidence rate ratio
AIC/N: Akaike information coefficient/sample size
Model 1: Unadjusted model
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division,
hospital size, year of discharge
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and
convulsions
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Table 20: Sub-group analysis: Zero-Inflated Poisson model for post-discharge health care
utilization during one-year follow-up period
Any visit

Rehospitalization

Emergency
department
IRR (95% C.I.)
Zero-inflated Poisson model
0.9 (0.7-1.2)
0.8 (0.6-0.97)
0.9 (0.7-1.2)

Outpatient
visits

Model 1
-Late preterm
0.8 (0.4-1.5)
births (Ref) vs.
NOWS
AIC/N
0.904
0.387
0.684
1.438
Model 2
Late preterm
0.9 (0.7-1.1)
0.7 (0.6-0.9)
0.9 (0.7-1.1)
0.8 (0.6-1.2)
births (Ref) vs.
NOWS
AIC/N
0.893
0.383
0.675
1.390
Model 3
Late preterm
0.9 (0.7-1.1)
0.8 (0.6-0.9)
0.9 (0.7-1.1)
0.8 (0.6-1.1)
births (Ref) vs.
NOWS
AIC/N
0.893
0.382
0.675
1.389
IRR: Incidence rate ratio
AIC/N: Akaike information coefficient/sample size
Model 1: Unadjusted model
Model 2: Adjusted for sex, race, insurance type, urban-rural status, census division,
hospital size, year of discharge
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and
convulsions
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Mean time to the first emergency visit in the NOWS group was 153 (SD: 112) days
as opposed to 154 (SD: 113) days in the late preterm group and 157 (SD: 116) days in the
uncomplicated birth group (p=0.53). The mean time to the first rehospitalization was 71.9
(SD: 105) days in the NOWS group, 52 (SD: 86) days in the late preterm group, and 63.3
(SD: 89.1) days in the uncomplicated birth group (p<0.05). These means reflect the average
number of days until the first event for infants who had the specific event (emergency
department visit or rehospitalization). The Kaplan-Meier curves for rehospitalization and
emergency department visits are shown in Figure 8. There were significant differences in
the time to event for both emergency department visit and rehospitalization across the study
groups based on the log-rank test of equality of survival functions (p<0.001).
Using Cox proportional-hazards regression, we estimated the hazard ratios (HR) of
outcomes across the study groups (i. emergency visit and ii. rehospitalization, Table 21).
There were no significant differences in the hazard ratios for emergency department visits
in the NOWS group compared to the uncomplicated birth group across all unadjusted and
adjusted Cox proportional-hazards regression models. In the sub-group analysis,
comparing NOWS group to the late preterm group, we did not observe any significant
difference in the hazard ratio for emergency department visits.
The hazard rate for rehospitalization was significantly higher in the NOWS group
compared to the uncomplicated birth group in the unadjusted model (HR: 2.0, 95% C.I.:
1.6-2.5). The association remained significant even after adjustment for demographic
characteristics (HR: 1.5, 95% C.I.: 1.2-1.9), and medical conditions (HR: 1.4, 95% C.I.:
1.1-1.8). In the sub-group analysis, the hazard rate for rehospitalization in the NOWS group
was not statistically significant when compared to the late preterm group in the unadjusted
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analysis. However, after adjusting for other confounders we observed that the HR for
rehospitalization was lower in the NOWS group compared to the late preterm group (Model
3, HR: 0.7, 95% C.I.: 0.6-0.8).
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Table 21: Survival analysis: Time to first incidence of post-discharge health care utilization
across study groups during one-year follow-up period
Cox proportional-hazards
regression
Model 1
Uncomplicated births (Ref) vs.
NOWS
Uncomplicated births (Ref) vs.
Late preterm births
Model 2
Uncomplicated births (Ref) vs.
NOWS
Uncomplicated births (Ref) vs.
Late preterm births
Model 3
Uncomplicated births (Ref) vs.
NOWS
Uncomplicated births (Ref) vs.
Late preterm births

Emergency visit
HR (95% C.I.)

Rehospitalization
HR (95% C.I.)

1.2 (0.9-1.7)

2.0 (1.6-2.5)

1.3 (1.1-1.5)

2.4 (2.0-2.9)

0.9 (0.7-1.2)

1.5 (1.2-1.9)

1.1 (1.0-1.3)

2.2 (1.9-2.7)

0.9 (0.7-1.1)

1.4 (1.1-1.8)

1.1 (0.9-1.2)

2.0 (1.7-2.4)

Sub-group analysis*
Model 1
Late preterm births (Ref) vs.
1.0 (0.7-1.4)
0.8 (0.7-1.1)
NOWS
Model 2
Late preterm births (Ref) vs.
0.8 (0.7-1.1)
0.7 (0.6-0.8)
NOWS
Model 3
Late preterm births (Ref) vs.
0.8 (0.7-1.1)
0.7 (0.6-0.8)
NOWS
Model 1: Unadjusted model
Model 2: Adjusted for LOS, sex, race, insurance type, urban rural status, census division,
hospital size, year of discharge
Model 3: Model 2 + respiratory condition, feeding problem, jaundice, sepsis, and
convulsions
*Models 2 and 3 also include initial LOS for the sub-group analysis
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Figure 8: Kaplan-Meier survival curves by study groups. A: Emergency department visit B. Rehospitalization
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4.3: Results for Specific Aim 2
Table 22 describes the baseline characteristics of the NOWS group divided across
infants who received pharmacologic treatment (received methadone, morphine, tincture of
opium and/or phenobarbital, henceforth termed “Treated-For-NOWS”) and infants who
did not receive pharmacological treatment for NOWS (Not-Treated-For-NOWS). This subgroup (Treated-For-NOWS) accounted for 34% of the infants in the NOWS group. There
were no significant differences between infants who were Treated-For-NOWS and those
who were Not-Treated-For-NOWS with respect to sex, race, or urban-rural status (p>0.05).
Statistically significant differences were present between these two groups with respect to
type of insurance, census region, and hospital size (p<0.05).
The differences in characteristics of the primary medical encounter by
pharmacological treatment of NOWS is presented in Table 23. Infants in the Treated-ForNOWS group had significantly longer LOS in the hospital following birth, compared to
Not-Treated-for-NOWS group (21.9 days vs. 12.2 days, p<0.001). Additionally, the
median cost for those in the Treated-For-NOWS group was approximately $52,000,
compared to $10,000 in the Not-Treated-For-NOWS group.
Overall, a larger proportion of infants in the Treated-For-NOWS group had medical
conditions, such as respiratory problems, convulsions, feeding difficulties, and sepsis (all
p-values <0.001). Observed respiratory problems within this group included respiratory
distress syndrome, transient tachypnea of newborn, and other unspecified respiratory
condition. A high proportion of infants in both groups had jaundice (35%, p=0.74).
Medications received during the pharmacological treatment are presented in Table
24. Among, infants who were diagnosed with NOWS a majority received either morphine
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or methadone (31%) followed by antibiotics (16%) and phenobarbital (6%). Morphine was
the most common medication of choice for pharmacologic management treatment of
NOWS (72.5%). Infants in the Treated-For-NOWS group were also administered
benzodiazepines and antibiotics at significantly higher rates than those in the Not-TreatedFor-NOWS group (p<0.001).
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Table 22: Description of demographic characteristics and patient care setting in infants
diagnosed with now based on pharmacologic treatment

Sex
Male
Female
Race
Caucasian
African American
Hispanic
Native American
Other
Insurance type
Medicaid/ Medicaid MC
Commercial
Other
Census region
Midwest
Northeast
South
West
Urban rural status
Urban
Rural
Hospital size (number of
beds)
Less than 100
100-299
Greater than 300

NOWS
(n=3,526)

Treated-ForNOWS
(n=1,203)

52.5%
47.5%

54.1%
45.9%

79.4%
5.9%
0.8%
2.7%
11.3%

78.5%
4.9%
0.8%
3.1%
12.8%

69.1%
11.9%
18.9%

73.2%
9.8%
17.0%

16.9%
44.2%
23.5%
15.4%

10.4%
42.0%
25.0%
22.6%

84.8%
15.2%

84.5%
15.5%

7.4%
28.4%
64.2%

4.0%
31.3%
64.8%
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Not-Treated- pFor-NOWS value
(n=2,323)
0.170
51.7%
48.3%
0.099
79.9%
6.4%
0.8%
2.5%
10.5%
0.001
67.0%
13.0%
19.9%
<0.001
20.3%
45.3%
22.8%
11.6%
0.683
85.0%
15.0%
<0.001
9.2%
27.0%
63.9%

Table 23: Description of primary medical encounter by status of pharmacologic treatment
for NOWS
Variable

NOWS
(n=3,526)

LOS (days)
Total Charges in dollars*
(median)

14.9 (11.5)
$24,944

Treated-ForNOWS
(n=1,203)
Mean (SD)
19 (11.6)
$60,355

Not-Treated- pFor-NOWS value
(n=2,323)
11.4 (9.7)
$11,989

<0.001
<0.001

%
Gestational age at delivery
33 weeks to less than 37
weeks
Any respiratory problems
Type of respiratory
problems
Respiratory distress
syndrome
Transient tachypnea of
newborn
Respiratory condition of
newborn (unspecified)
Other specified respiratory
condition
Convulsions
Feeding difficulties
Jaundice
Sepsis

0.303
14.7%

15.5%

14.3%

20.8%

27.5%

17.4%

<0.001

4.8%

7.5%

3.4%

<0.001

11.3%

13.8%

9.9%

<0.001

0.8%

1.2%

0.7%

0.106

7.5%

10.2%

6.1%

<0.001

1.2%
18.4%
35.6%
4.6%

1.9%
26.2%
36.0%
6.9%

0.8%
14.4%
35.4%
3.4%

0.005
<0.001
0.740
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Table 24: Description of medication received during primary medical encounter by status
of pharmacologic treatment for NOWS
NOWS
(n=3,526)
Received morphine
Received methadone
Received opium
Received morphine or
methadone
Received phenobarbital
Received benzodiazepines
Received antibiotics

24.7%
7.9%
0.2%
31.2%

Treated-ForNOWS
(n=1,203)
72.5%
23.3%
0.7%
91.4%

Not-TreatedFor-NOWS
(n=2,323)
-

6.4%
1.5%
16.3%

18.7%
3.2%
25.6%

0.6%
11.4%
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pvalue

<0.001
<0.001

4.3.1 Analysis of the association between pharmacological treatment of NOWS and postdischarge health care utilization
A wide variability in post-discharge healthcare utilization (Table 25) across infants
who received/did not receive pharmacological treatment for NOWS was found. Any
emergency department visit (10.1% vs. 6.2%, p<0.001) and the mean number of emergency
department visits (0.164 vs. 0.089, p<0.001) in the one-year follow-up period were
significantly higher in Treated-For-NOWS group when compared to Not-Treated-ForNOWS group. Treated-For-NOWS group also had higher any composite visit (13.0% vs.
9.0%, p<0.001) and had higher mean number of composite visits (0.211 vs. 0.129,
p<0.001) compared to Not-Treated-For-NOWS group. We did not find any significant
differences in the mean number of rehospitalization events or any post-discharge
rehospitalization based on their pharmacological treatment status. Furthermore, we did not
observe any significant differences in the rates of outpatients visits based on the
pharmacological treatment status of the infant.
4.3.2 Analysis of the association between NOWS related severity measures and postdischarge healthcare utilization
In the unadjusted logistic regression model (Table 26), medical conditions, such as
respiratory conditions (OR: 1.8, 95% C.I.: 1.1-2.9), feeding difficulties (OR: 1.6, 95% C.I.:
1.1-2.5), and receiving antibiotics (OR: 1.4, 95% C.I.: 1.1-1.9) were associated with higher
odds of rehospitalization. We did not observe any associations between the
pharmacological treatment, LOS, prematurity, medications (phenobarbital, barbiturates),
sepsis and rehospitalization. In the adjusted model, these associations were not statistically
significant either. In both the unadjusted and adjusted models, there was no association
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between odds of any 30-day rehospitalization and medication received, LOS, prematurity,
or medical conditions diagnosed at initial hospital stay.
A significant association between pharmacologic treatment for NOWS and
emergency department visit was observed (OR: 1.6, 95% C.I.: 1.02-2.8; Table 27).
However, in the adjusted models, the association was not statistically significant (OR: 1.4,
95% C.I.: 0.9-2.1). Infants who had a respiratory condition at birth were found to have
higher odds of 30-day emergency department visit. However, the association was not
significant after controlling for other factors. In the unadjusted logistic regression model,
we did not observe any effect of LOS, prematurity, medications (phenobarbital,
barbiturates, and antibiotics), and medical conditions on any emergency department visit.
Receiving benzodiazepines (OR: 2.1, 95% C.I.: 1.1-3.8) and having respiratory
conditions (OR: 1.5, 95% C.I.: 1.1-2.0) were associated with higher odds of any composite
visit during the post-discharge follow-up period (Table 28). Pharmacologic treatment of
NOWS, LOS, feeding difficulties, and jaundice showed marginal association with any
composite visits. In the full model, these associations were not statistically significant.
Respiratory conditions and LOS were associated with higher odds of any 30-day visit.
After adjustment, marginal statistical significances was observed for both of these factors.
We did not observe any statistically significant association between majority of the
NOWS severity measures and outpatient visits (Table 29). However, in the adjusted model,
receiving benzodiazepines was found to be associated with higher odds of outpatient visits
(OR: 2.6, 95% C.I.: 1.2-5.2)
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Table 25: Description of post-discharge healthcare utilization in infants diagnosed with
NOWS by status of pharmacological treatment for NOWS
Variable

Rehospitalization
Mean rehospitalization
Any rehospitalization
Any 30-day
rehospitalization
Emergency Department
Mean emergency
department
Any emergency
department visit
Any 30-day emergency
department visit
Any (Rehospitalization
or Emergency
Department)
Total mean visits
(Rehospitalization and
Emergency Department)
Any visit
(Rehospitalization and
Emergency Department)
Any 30-day visit
(Rehospitalization and
Emergency Department)
Outpatient visit
Mean outpatient visit per
1000
Any outpatient

NOWS
(n=3,526)

Treated-ForNOWS
(n=1,203)

Not-TreatedFor-NOWS
(n=2,323)

pvalue

0.042 (0.22)
3.8%
2.4%

0.047 (0.24)
4.2%
2.2%

0.040 (0.21)
3.7%
2.5%

0.322
0.466
0.536

0.114 (0.48)

0.164 (0.60)

0.089 (0.39)

<0.001

7.5%

10.1%

6.2%

<0.001

2.0%

2.5%

1.8%

0.172

0.157 (0.56)

0.211 (0.70)

0.129 (0.47)

<0.001

10.4%

13.0%

9.0%

<0.001

4.3%

4.5%

4.1%

0.619

0.371 (1.45)

0.40 (1.56)

0.36 (1.38)

0.372

12.4%

12.2%

12.5%

0.821
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Table 26: Logistic regression model: Examination of factors affecting rehospitalization in
infants with NOWS
Any rehospitalization
Unadjusted
Adjusted*
OR (95%
OR (95%
C.I.)
C.I.)
1.1 (0.7-1.9) 1.0 (0.6-1.7)
1.0 (0.991.0 (0.981.02)
1.0)
0.4 (0.2-1.2)
2.1 (0.9-5.2) 2.3 (0.8-6.6)

30-day rehospitalization
Unadjusted
Adjusted*
OR (95%
OR (95%
C.I.)
C.I.)
Treated-For-NOWS
0.9 (0.4-1.4) 0.8 (0.4-1.5)
LOS
1.0 (0.991.0 (0.971.02)
1.0)
Received phenobarbital
0.4 (1.0-1.3)
Received benzodiazepine
2.6 (0.9-7.7)
2.9 (0.811.2)
Any respiratory condition 1.8 (1.1-2.9) 1.5 (0.8-2.5) 1.7 (0.9-3.2) 1.6 (.0.8-3.2)
Feeding difficulties
1.6 (1.1-2.5) 1.5 (1.0-2.2) 1.6 (0.9-2.8) 1.2 (0.9-1.6)
Prematurity
1.1 (0.7-1.6) 0.8 (0.5-1.2) 1.0 (0.6-1.6) 0.7 (0.4-1.3)
Received antibiotic
1.4 (1.1-1.9) 1.2 (0.8-1.7) 1.1 (0.7-1.8) 0.8 (0.4-1.5)
Jaundice
1.4 (1.0-1.9) 1.3 (0.9-2.0) 1.4 (0.9-2.3) 1.4 (0.8-2.3)
Sepsis
1.1 (0.4-3.6) 0.8 (0.3-2.5) 1.9 (0.7-5.6) 1.5 (0.6-4.0)
*Adjusted for sex, race, insurance type, year, census division, urban rural status

Table 27: Logistic regression model: Examination of factors affecting emergency
department visits in infants with NOWS
Any emergency
30-day emergency
department visit
department visit
Unadjusted
Adjusted
Unadjusted
Adjusted
OR (95%
OR (95%
OR (95%
OR (95%
C.I.)
C.I.)
C.I.)
C.I.)
Treated-For-NOWS
1.6 (1.021.4 (0.9-2.1) 1.4 (0.8-2.4) 1.0 (0.5-2.0)
2.8)
LOS
1.0 (0.991.0 (0.981.01 (1.01.0 (0.991.0)
1.01)
1.03)
1.03)
Received phenobarbital
0.7 (0.4-1.4)
0.4 (0.1-1.4)
Received benzodiazepine 1.6 (0.6-4.0) 0.2 (0.5-2.9) 0.9 (0.1-6.2) 0.8 (0.2-3.9)
Any respiratory condition 1.4 (0.8-2.2) 1.1 (0.8-1.5) 1.9 (1.1-3.3) 1.6 (0.8-2.9)
Feeding difficulties
1.2 (0.8-1.8) 1.0 (0.7-1.5) 1.2 (0.6-2.2) 0.7 (0.4-1.4)
Prematurity
1.2 (0.8-1.8) 1.0 (0.7-1.5) 1.4 (0.8-2.4) 1.2 (0.7-2.0)
Received antibiotic
1.3 (0.8-2.0) 1.0 (0.7-1.5) 1.4 (0.7-2.5) 0.9 (0.4-2.0)
Jaundice
1.1 (0.7-1.6) 1.0 (0.7-1.4) 1.2 (0.7-2.1) 1.0 (0.6-1.7)
Sepsis
1.3 (0.7-2.3) 1.1 (0.6-2.1) 1.9 (0.6-6.1) 1.5 (0.5-4.7)
*Adjusted for sex, race, insurance type, year, census division, urban rural status
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Table 28: Logistic regression model: Examination of factors affecting any composite visit
in infants with NOWS

Treated-For-NOWS
LOS

Any visit (Emergency
department or
rehospitalization)
Unadjusted
Adjusted
OR (95%
OR (95%
C.I.)
C.I.)
1.4 (0.991.2 (0.8-1.9)
2.3)
1.0 (1.00.99 (0.981.02)
1.01)
0.6 (0.3-1.2)
2.1 (1.1-3.8) 1.7 (0.8-3.4)
1.5 (1.1-2.0) 1.2 (0.9-1.6)

Any 30-day visit
(Emergency department
or rehospitalization)
Unadjusted
Adjusted
OR (95%
OR (95%
C.I.)
C.I.)
1.1 (0.7-1.6) 0.9 (0.5-1.6)
1.0 (1.01.02)
0.4 (0.1-1.1)
1.9 (0.9-4.1)
1.8 (1.2-2.9)

1.0 (0.991.02)
Received phenobarbital
Received benzodiazepine
1.8 (0.7-4.8)
Any respiratory condition
1.6 (0.962.6)
Feeding difficulties
1.3 (0.9-1.8) 1.1 (0.8 -1.5) 1.4 (0.8-2.3) 1.0 (0.7-1.3)
Prematurity
1.2 (0.8-1.6) 0.9 (0.7-1.3) 1.2 (0.8-1.7) 0.9 (0.6-1.4)
Received antibiotic
1.4 (0.9-2.0) 1.1 (0.8-1.5) 1.3 (0.9-1.9) 0.9 (0.6-1.5)
Jaundice
1.1 (0.9-1.5) 1.1 (0.9-1.4) 1.3 (0.9-1.8) 1.1 (0.8-3.2)
Sepsis
1.3 (0.7-2.3) 1.1 (0.6-1.9) 2.1 (0.9-4.6) 1.5 (0.7-3.2)
*Adjusted for sex, race, insurance type, year, census division, urban rural status

Table 29: Logistic regression model: Examination of factors affecting any outpatient visits
in infants with NOWS
Any outpatient visit
Unadjusted
Adjusted
OR (95% C.I.)
OR (95% C.I.)
Treated-For-NOWS
1.0 (0.7-1.4)
1.0 (0.7-1.5)
LOS
1.0 (0.97-1.0)
1.0 (0.98-1.01)
Received phenobarbital
0.6 (0.2-1.1)
Received benzodiazepine
1.9 (0.7-5.0)
2.6 (1.2-5.2)
Any respiratory condition
1.1 (0.8-1.5)
1.1 (0.8-1.5)
Feeding difficulties
1.2 (0.8-1.9)
1.1 (0.8-1.5)
Prematurity
1.0 (0.7-1.4)
0.9 (0.7-1.2)
Received antibiotic
1.3 (0.9-1.8)
0.1 (0.7-1.5)
Jaundice
0.7 (0.5-0.97)
1.1 (0.8-1.1)
Sepsis
0.9 (0.5-1.6)
0.7 (0.4-1.3)
*Adjusted for sex, race, insurance type, year, census division, urban rural status
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4.3.4 Analysis of the association between NOWS related severity measures and rates of
post-discharge health care utilization: Zero-inflated Poisson regression models
In Table 30, the association between NOWS severity measures and rates of postdischarge health care utilization during the one-year follow-up is reported. In the
unadjusted model, the infants who received pharmacologic treatment for NOWS (IRR: 1.5,
95% C.I.: 1.01-1.4) and had respiratory condition (IRR: 1.5, 95% C.I.: 1.2-1.8) had higher
incidence rates for any composite visit. In the full model, presence of a respiratory
condition was associated with a statistically significant increase in incidence of any
composite visit (IRR: 1.2, 95% C.I.: 1.04-1.5) compared to those who did not have a
respiratory condition. Further, infants who received antibiotics, those who had a diagnosis
of a respiratory condition, and feeding difficulties also had higher incidence rates of
rehospitalization. In the full model, there was a marginal effect of respiratory condition on
increase in incidence of any rehospitalization in the NOWS group (IRR: 1.7, 95% C.I.: 1.02.7). In the unadjusted model, infants who had a respiratory condition had higher incidence
rates of emergency department visits (IRR: 1.4, 95% C.I.: 1.04-1.8). Infants with feeding
difficulties had higher incidence rates of outpatient visits (IRR: 1.5, 95% C.I.: 1.2-1.8). The
association remained significant after adjustment for other factors in the full model.
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Table 30: Zero-inflated Poisson regression model: Analysis of factors affecting rates of
post-discharge health care utilization in infants with NOWS
Any visit

Treated-For-NOWS
LOS
Received
phenobarbital
Received
benzodiazepine
Any respiratory
condition
Feeding difficulties
Prematurity
Received antibiotic
Jaundice
Sepsis

Rehospitalizati
Emergency
on
department
IRR (95% C.I.)
Zero inflated Poisson model (unadjusted)
1.5 (1.01-1.4)
1.2 (0.7-1.9)
1.7 (1.0-2.7)
1.0 (0.99-1.01) 1.0 (0.99-1.01) 1.0 (0.99-1.02)
0.6 (0.3-1.1)
0.4 (0.1-1.1)
0.6 (0.3-1.1)

Outpatient
visits

1.2 (0.97-1.5)
1.0 (0.98-1.0)
1.2 (0.8-1.7)

1.2 (0.7-2.1)

2.3 (0.9-5.6)

1.2 (0.6-2.4)

1.1 (0.5-2.3)

1.5 (1.2-1.8)

1.9 (1.1-3.1)

1.4 (1.04-1.8)

1.0 (0.8-1.4)

1.1 (0.8-1.4)
1.3 (0.99-1.7)
1.2 (0.9-1.5)
1.1 (0.9-1.3)
0.9 (0.6-1.5)

1.5 (1.1-2.0)
0.2 (0.8-1.9)
1.6 (1.1-2.2)
1.4 (1.0-1.8)
1.0 (0.3-2.9)

1.0 (0.7-1.2)
1.2 (0.99-1.5)
1.1 (0.8-1.5)
1.0 (0.8-1.3)
0.9 (0.6-1.5)

1.5 (1.2-1.8)
0.9 (0.7-1.3)
0.9 (0.7-1.3)
0.9 (0.7-1.1)
0.5 (0.3-0.9)

Zero inflated Poisson model (adjusted)*
Treated-For-NOWS
1.2 (0.8-1.7)
0.9 (0.5-1.5)
1.4 (0.9-2.2)
1.1 (0.9-1.5)
LOS
1.0 (0.99-1.01) 1.0 (0.99-1.01) 1.0 (0.98-1.02)
1.0 (0.99-1.0)
Received
1.5 (0.8-2.8)
2.6 (0.9-7.6)
1.2 (0.5-2.7)
1.2 (0.7-2.1)
benzodiazepine
Any respiratory
1.2 (1.04-1.5)
1.7 (1.0-2.7)
1.1 (0.9-1.4)
1.0 (0.7-1.5)
condition
Feeding difficulties
0.9 (0.7-1.2)
1.3 (0.9-1.6)
0.8 (0.6-1.1)
1.5 (1.2-1.8)
Prematurity
1.1 (0.8-1.4)
1.0 (0.6-1.5)
1.1 (0.8-1.4)
0.9 (0.7-1.3)
Received antibiotic
1.1 (0.8-1.5)
1.3 (0.9-1.9)
1.1 (0.7-1.6)
0.8 (0.6-1.0)
Jaundice
1.1 (0.9-1.4)
1.3 (0.9-1.8)
1.0 (0.8-1.3)
1.0 (0.8-1.2)
Sepsis
0.9 (0.5-1.6)
0.7 (0.2-1.9)
1.0 (0.6-1.9)
0.5 (0.3-0.8)
IRR: Incidence rate ratio
*Adjusted for sex, race, insurance type, urban-rural status, census division, hospital size,
year of discharge
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4.3.4 Operationalization of LOS: the non-linear effect of LOS on post-discharge
healthcare utilization:
LOS was operationalized by four transformations to account for possible non-linear
effects on post-discharge healthcare utilization. We observed a non-linear effect of LOS
on short-term post-discharge health care utilization. As presented in Figure 9, within the
NOWS group, the probability of any event in the 30-day post-discharge period varied for
emergency room visits and rehospitalization. The probability of emergency room visits
decreases when LOS increases from three to four days to five to six days. This probability
increased with increasing LOS. The risk then stabilizes at infants with LOS more than 20
days. For hospital readmission, the risk is significantly higher for infants with short LOS
(risk increases exponentially for age at discharge 3 to 7 days. The risk decreases as the LOS
increases to at least 10 to 15 days. After 15 days, the risk increases along with LOS. The
heterogeneity of non-linear risk for emergency room visit, and rehospitalization limits the
interpretation of non-linear association between LOS and composite post-discharge
healthcare utilization.
It should also be taken into account that using non-linear transformation for LOS
could lead to overfitting. This is more likely in the event that prematurity, pharmacological
treatment for NOWS, and other diagnoses are factored into a regression model. With this
information available, it is possible that a linear form of LOS could sufficiently describe
the variation in post-discharge health care utilization in the NOWS group.
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Figure 9: Assessing the non-linear relationship between infant length of stay and short-term post-discharge healthcare utilization
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4.4 Sensitivity analysis:
4.4.1 Examination of the effect of LOS as a selection criterion on post-discharge
healthcare utilization
Approximately 25% of the infants in the late preterm group had LOS less than three
days. We classified the late preterm group into two categories (i.e., LOS less than three
days and LOS more than or equal to three days) to compare their post-discharge health care
utilization. Besides any emergency visits, the rates of post-discharge health care utilization
were higher (p<0.05) in the infants with LOS less than three days across all other outcomes
(Table 31).
In our selection criteria, we had excluded NOWS infants with LOS less than three
days. As the LOS was shown to affect post-discharge healthcare utilization, the inclusion
of infants with LOS less than 3 days in the late preterm group could have led to differences
in post-discharge health care utilization. We performed a sensitivity analysis to compare
the differences in post-discharge health care utilization between NOWS group and the late
preterm group after the exclusion of infants in the late preterm group whose LOS was less
than three days. The results are shown in Table 32.
Based on the sensitivity analysis, we observed that the exclusion of late preterm
infants with LOS less than 3 days did not produce a significant difference in the postdischarge health care utilization across the two study groups. In some of the comparisons
(e.g.: 30-day rehospitalization, any rehospitalization) there were substantial changes in the
p-value across the sensitivity analysis. These changes were likely due larger change in the
proportion of rehospitalization events in the sensitivity analysis.
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We performed a multivariable logistic regression to assess if any confounders were
affecting the results we observed from the sensitivity analysis (Table 34). In the original
analysis (Comparison of post-discharge health care utilization in NOWS group vs. late
preterm group: Tables 15, 16, and 17) there were statistically significant differences in
post-discharge health care utilization between NOWS and late preterm group after
adjustment for confounders. Specifically, NOWS group had lower odds of any
rehospitalization and any composite visit. After excluding late preterm infants with LOS
less than 3 days, the association was still observed to be statistically significant but the
point estimate of the odds ratio was slightly lower (Table 33). Based on these findings we
can conclude that there is heterogeneity with respect to post-discharge health care
utilization in the late preterm group based on the LOS of the infant. However, the
differences did not substantially affect the comparison of post-discharge healthcare
utilization between NOWS and late preterm groups.
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Table 31: Proportion of late preterm infants who had post-discharge healthcare utilization
stratified by LOS (cut-off <3 days)
Any
Any
Any
emergency rehospitalization visit

LOS < 3
days
LOS ≥ 3
days
P-value

30-day
30-day
Any
emergency rehospitalization 30-day
visit

8.1%

4.8%

12.1%

2.3%

3.9%

6.0%

7.7%

3.9%

10.8%

1.7%

2.4%

3.9%

0.31

0.003

0.008

0.002

<0.001

<0.001

Table 32: Sensitivity analysis: Differences in post-discharge healthcare utilization in
NOWS group compared to late preterm group
Any
Any
Any
emergency rehospitalization visit

NOWS
7.5%
3.8%
10.4%
Late
7.6%
4.3%
11.1%
preterm
P-value
0.86
0.21
0.19
Sensitivity analysis (late preterm LOS ≥ 3 days)
NOWS
7.5%
3.8%
10.4%
Late
7.7%
3.9%
10.9%
preterm
P-value
0.69
0.74
0.36
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30-day
30-day
Any
emergency rehospitalization 30-day
visit

2.0%
1.8%

2.4%
2.9%

4.3%
4.5%

0.23

0.07

0.48

2.0%
1.7%

2.4%
2.4%

4.3%
3.9%

0.13

0.94

0.36

Table 33: Sensitivity analysis: Logistic regression: Post-discharge healthcare utilization
in NOWS group compared to late preterm group
Any emergency

Any
rehospitalization
OR (95% C.I.)
0.8 (0.6 - 0.)

Late preterm (Ref) vs.
0.8 (0.7 - 1.1)
NOWS
Sensitivity analysis (late preterm LOS ≥ 3 days)
Late preterm (Ref) vs.
0.9 (0.7 - 1.1)
0.8 (0.7 - 1.0)
NOWS
Emergency visit
(30-day)

Rehospitalization
(30-day)
OR (95% C.I.)
0.7 (0.5 - 1.0)

Any visit
0.8 (0.6 –
0.97)
0.8 (0.7 0.99)
Any visit (30day)

Late preterm (Ref) vs.
1.1 (0.9 - 1.5)
0.9 (0.7 - 1.1)
NOWS
Sensitivity analysis (late preterm LOS ≥ 3 days)
Late preterm (Ref) vs.
1.1 (0.9 - 1.6)
0.9 (0.7 - 1.2)
1.0 (0.8 - 1.3)
NOWS
Logistic regression model adjusted for sex, insurance type, race, urban rural status, census
division and year.
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4.4.2 Assessment of the difference in rates of pharmacological treatment of NOWS across
different hospitals and its impact on post-discharge health care utilization
In 55.8% of the hospitals, the rates of pharmacological management of NOWS was
less than 25%, which is surprisingly low. We categorized the study sample into two groups:
a) infants admitted/born at a hospital where ≥25% of NOWS cases received
pharmacological treatment (n=2,029) b) infants admitted/born at a hospital where <25% of
NOWS cases received pharmacological treatment (n=1,497). There were no statistical
differences in the geographical distribution, urban rural status, and size (number of beds)
of these hospital groups.
We conducted a sensitivity analysis to examine the differences in the post-discharge
healthcare utilization across between these two hospital groups. The outcome variables that
were examined were 30-day composite (emergency department visit or hospital
readmission) healthcare utilization and any composite healthcare utilization. We observed
significantly higher composite health care utilization (one-year follow-up period) in infants
who were admitted/born into a hospital where more than 25% of the NOWS diagnosed
infants received pharmacological treatment compared to the group where pharmacological
NOWS treatment rate was less than 25% (Any composite visit during one-year follow-up
period: 12.7% vs. 7.2%, p<0.001). There was no difference in 30-day composite health
care utilization across these two hospital groups (Table 34).
We restricted our sample to infants who were admitted to hospitals where the
pharmacological treatment rate was ≥25% and compared their post-discharge health care
utilization with the uncomplicated birth and late preterm groups. After the application of
the exclusion criteria, the remaining NOWS group (infants managed in hospitals where

109

NOWS treatment rates were more than or equal to 25%) had higher odds of one-year
composite health care utilization compared to uncomplicated birth group in the unadjusted
analysis (OR: 1.9, 95% C.I.: 1.4-2.5). However, the association was not statistically
significant after adjusting for other covariates (Model 2 and Model 3 as explained in the
methods section). The NOWS group had higher odds of 30-day composite health care
utilization compared to compared to uncomplicated birth group across all the unadjusted
and adjusted logistic regression models (Model 3: OR: 1.4, 95% C.I.: 1.02-1.8).
Furthermore, we also evaluated the association between pharmacological treatment
and post-discharge health care utilization stratified across these hospital groups (Table 35).
There was no difference in the composite healthcare utilization (both 30-day and one-year)
based on the pharmacological treatment when stratified by the hospital groups in the
unadjusted analysis. However, after controlling for other factors we observed that in
hospitals that had lower treatment rates of NOWS, pharmacological treatment of NOWS
was associated with lower odds of 30-day composite health care utilization (OR: 0.3, 95%
C.I.: 0.1-0.8).
The results from the sensitivity analysis were similar to the findings obtained in the
main analysis (Table 17). We do note that there were some differences in the health care
utilization in infants based on the hospital they were treated. The regression models in our
study utilizes a hospital random effects model (cluster effects of hospital) which would
take into account these differences in outcomes.
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Table 34: Sensitivity analysis: Proportion of infants in the NOWS group who had any
composite healthcare utilization based on NOWS pharmacological treatment rates (<25%)
of hospitals

Any visit
Any 30-day visit

Facilities with ≥25%
of NOWS cases
treated
12.7%
4.7%

Facilities with <25 of
NOWS cases treated

p-value

7.2%
3.7%

<0.001
0.143

Table 35: Sensitivity analysis: Logistic regression model: Association between postdischarge health care utilization and pharmacological treatment of NOWS stratified by
NOWS treatment rates (<25%) of hospitals

Variable: TreatedFor-NOWS
Unadjusted model
Adjusted model

Facilities with ≥25% of NOWS Facilities with <25 of NOWS
cases treated
cases treated
Any visit
OR (95% C.I.)
1.3 (0.86 - 1.9)
0.7 (0.2 - 2.6)
1.3 (0.83 - 2.1)
0.5 (0.2 - 1.6)
Any 30-day visit
OR (95% C.I.)

Unadjusted model
1.1 (0.6 - 1.9)
0.5 (0.3 - 1.1)
Adjusted model
1.1 (0.6 - 2.1)
0.3 (0.1 - 0.8)
*Adjusted for sex, race, insurance type, year, census division, urban rural status
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4.4.3 Propensity score analysis for pharmacological management of NOWS:
Propensity scores for pharmacological treatment for NOWS were generated by
using the process described in the method section. The propensity score was used as a linear
covariate along with the pharmacological treatment for NOWS variable as predictor for
post-discharge health care utilization (any composite visit, any 30-day composite visit).
After adjusting for the propensity score, pharmacological treatment of NOWS was
associated with higher odds of any composite visit (OR: 1.4, 95% C.I.: 1.04-1.7) compared
to no pharmacological treatment. There was no association between pharmacological
treatment for NOWS and any 30-day composite health care utilization after adjusting for
propensity scores (OR: 0.9, 95% C.I.: 0.6-3).
4.4.4 Principal component analysis for NOWS severity factors:
The principal component analysis with pharmacological treatment of NOWS, LOS,
medications used (benzodiazepines), respiratory conditions, and feeding difficulties as
input variables yielded principal components which are listed in Table 36. The Table shows
the first three components where the eigenvalues are >1 and the absolute values of factor
loadings are >0.3. The first factor is loaded by pharmacological treatment of NOWS, LOS,
and feeding problems. The second factor is loaded with pharmacological treatment of
NOWS, use of benzodiazepines, respiratory condition of newborn, and feeding problems.
The third factor is loaded by transient tachypnea of newborn, respiratory distress syndrome,
respiratory condition of newborn, and other specified respiratory conditions. These three
components described a total of 49.5% of the variation of in the input variables.
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Table 36: Results of principal component analysis: components and factor loadings
Variable
Treated-For-NOWS
LOS
Benzodiazepine use
Respiratory distress
syndrome
Transient Tachypnea of
newborn
Respiratory condition of
newborn (unspecified)
Other specified
respiratory condition
Feeding problems

Component 1
0.50
0.56

Component 2
-0.36

Component 3

-0.45
-0.51
0.52
0.49

-0.35
-0.58

0.42

0.31

These components were considered NOWS severity measures (uncorrelated) and
their association with post-discharge health care utilization was examined (Table 37). We
observed that the first component was significantly associated with higher odds of any
composite visit during the one-year follow-up period (OR: 1.2, 95% C.I.: 1.1-1.3). The
same component was significantly associated with any 30-day composite visit (OR: 1.2,
95% C.I.: 1.1-1.3).
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Table 37: Logistic regression model: Association between post-discharge health care
utilization and principal components as measure of NOWS severity
Any visit

Any visit*

Any 30-day
visit
OR (95% C.I.)

Any 30-day
visit*

Component 1

1.2 (1.1-1.2)

1.1 (1.04-1.2)

1.2 (1.1-1.3)

1.1 (0.99-1.3)

Component 2

1.0 (0.9-1.1)

1.0 (0.9-1.1)

1.1 (0.98-1.3)

1.1 (0.95-1.2)

Component 3

1.0 (0.9-1.1)

0.9 (0.9-1.03)

1.0 (0.9-1.1)

1.0 (0.8-1.2)

*Adjusted for prematurity, sepsis, jaundice, use of antibiotics, sex, insurance status, race,
bed size, year, and census division
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CHAPTER 5: DISCUSSION
In this chapter, we discuss the findings of our study. Discussion of the results is
presented first and divided based on the specific aims of the study, followed by the
limitations of the study, the study’s impact and future directions.
5.1: Discussion for Specific Aim 1
The trends and geographic distribution of NOWS births matched the growing
opioid epidemic in the US. Between 2011 and 2016, the incidence of NOWS increased
approximately four fold in several census divisions in the US. Results from our analysis
show that rates of NOWS are consistently above 15 per 1000 births and reach up to, and
over, 30 per 1000 births in New England, Middle Atlantic, East South Central, and South
Atlantic regions. In contrast, during the same period, the rates of late preterm birth
remained relatively constant at approximately 6 per 100 births.
The growing rate of NOWS reflects the ongoing opioid epidemic in the US.
Increasing rates of opioid prescription across the U.S. has been shown by previous
reports.108-111. Data has recently shown a peak in illicit opioid use (heroin and other
synthetic opioids) in the northeast U.S. around the year 2015, dramatically increasing the
opioid overdose rates in large swaths of communities across that region.112 The increase in
illicit opioid use and misuse of prescription opioids in the general population was matched
by an increase in opioid use during pregnancy, which closely correlates to increase in the
rates of NOWS. Using the Healthcare Cost and Utilization project (HCUP) Kids data,
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Patrick et al. reported a three-fold increase in the rates of NOWS between the years 2009
and 2012 across the US.43,113
Figure 10 shows the rates of NOWS derived from our findings compared to the
previous studies. Patrick et al. reported an increase in the rates of NOWS from
approximately 1.2 per 1000 births in the year 2000 to approximately 3.5 per 1000 births in
the year 2009.25 A similar growth of substance use disorder in mothers at delivery was
reported by Haight et al.114 Additionally, the rates of NOWS reported by Winkelman et al113
show significant overlap with the estimates reported by Patrick et al. (years 2004-2009).
The rates of NOWS observed in our study were significantly higher compared to the rates
reported by Winkelman et al. during the same study period. The denominator used for the
estimate of NOWS rates in our study is a subset of the total number of births that actually
occurred, which can cause the rates of NOWS to be potentially overestimated. Additionally,
the hospitals/health centers that were included in the study are not specifically weighted to
represent total national births, which may also cause the rates obtained in our study to be
different than previous estimates.
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Figure 10: Comparison of estimates of NOWS birth with results from existing literature
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There is a wide variability in the prescribing patterns of opioids across different
states in the US, which has led to significant variability in the incidence of NOWS across
the country. The geographic variability in NOWS incidence in our study are in accord with
findings from previous studies and matches the variation in the incidence of opioid
epidemic in the US.43,115 These reports show that the rates of opioid use are closely related
to the rates of NOWS, and policies that address the opioid epidemic could lead to lower
rates of NOWS.
Infants with NOWS differed significantly in terms of their baseline characteristics
compared to uncomplicated births and late preterm births. A higher proportion of infants
diagnosed with NOWS were Caucasian (79%) compared to late preterm birth and
uncomplicated births (53% and 57%, respectively). This difference in the rates of NOWS
reflects the difference in rates of opioid use, which has been reported to be higher in nonHispanic Whites.111 Our study also showed that Medicaid covered a majority of NOWS
cases (approximately 69%). Previous studies have reported similar findings, with one study
reporting up to 80% of the NOWS related payments were covered by Medicaid.44
Furthermore, our study shows that a majority of the NOWS births occurred in medical
centers/hospitals with a bed size of 300 or more. Infants with NOWS usually require a
greater level of medical attention, pharmacological management, and higher rates of
admission to the NICU to manage symptoms related to NOWS. This would require
admission to large hospital systems where these services are available, thus reflecting the
difference in the birthing hospital.
As expected, there were significant differences in healthcare utilization in infants
who were diagnosed with NOWS at birth compared to both control groups. If in utero
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exposure to opioids is confirmed, the patients are required to stay in the hospital for an
extended observation period (ranging from 72 to 96 hours) to examine the symptoms of
NOWS. Infants who are diagnosed with NOWS require significant pharmacologic and
non-pharmacologic management of the symptoms, which prolongs their hospital stay. For
infants requiring pharmacologic treatment, the LOS depends upon the severity of NOWS,
the amount of opioid treatment required to manage the symptoms, and any additional
complications present at birth. Similar to findings from previous studies, our study showed
that the average LOS for infants diagnosed with NOWS is approximately 15 days.
The amount of additional care required for NOWS is also reflected in the average
cost of the management of NOWS. There was a significant difference in cost (total charges)
for NOWS births compared to uncomplicated births (approximate median charges:
$24,900 vs. $3,100). The cost of management of late preterm birth was similar to NOWS,
as similar degrees of medical attention were needed for both groups. Furthermore,
respiratory problems, sepsis, and feeding difficulties were common in the late preterm
group. These conditions require greater medical attention and specialized care, which leads
to longer hospital stays and higher cost of treatment.
Post-discharge health care utilization in infants with NOWS showed consistent
trends over different measures of healthcare utilization. There was an increase in the rates
of post-discharge health care utilization in the NOWS group between the years 2011 and
2013 (from 8.5% to 13% for any composite visit and from 2.1% to 6.7% for any 30-day
composite visit), whereas the post-discharge rates in the late preterm group and
uncomplicated birth group remained fairly constant. This could have probably been
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because of the surge in the incidence of NOWS in that period while there were not enough
measures available in the hospitals to effectively diagnose and manage infants with NOWS.
Our study found that approximately 4% of infants with NOWS had hospital
readmission, compared to about 1.5% of the two control groups. Patrick et al. reported that
the overall one-year readmission rates in infants with NOWS was approximately 7.5%
compared to 4% in controls.36 While absolute readmission rates for the NOWS group in
our study were lower than that reported by Patrick et al., the ratio of readmission between
the NOWS and uncomplicated birth groups was approximately the same. Infants with
NOWS had significantly higher odds of hospital readmission compared to controls for both
one-year (OR: 1.7, 95% C.I. 1.3-2.2) and 30-day rehospitalizations (OR: 1.9 95% C.I.: 1.32.6). Similar findings were reported by Patrick et al. 2015 (30-day rehospitalization: OR:
2.5, 95% C.I.: 1.8-3.6)36, Hwang et al. (OR: 1.1: 95% C.I.: 1.04-1.2)116 and Liu et al.
(adjusted mean ratio: 4.2, 95% C.I.: 1.9-9.7)117. Using the Zero-inflated Poisson regression
models, consistent results were observed in the incidence rates of rehospitalizations for the
NOWS groups compared to the uncomplicated birth group. This evidence suggests
increased rehospitalization during the period surrounding the first year of life for the
NOWS group.
We observed higher rates of emergency department visits in the NOWS group
compared to the uncomplicated birth group, though, not as pronounced as the difference in
rehospitalizations between the groups. In the adjusted model, a marginally significant
association was observed for 30-day emergency department visits. Liu et al. reported an
adjusted mean ratio of 1.8 (95% C.I.: 1.5-2.2) for emergency department visit claims in the
ages between 4 and 12 months.117 Hwang et al. reported lower odds of emergency
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department visits in infants born to mothers with substance use disorders compared to
controls.116 However that study was not specific to withdrawal syndrome related to opioids,
which could have contributed to differences in the estimates of emergency department
visits.
The differences in the estimates of post-discharge health care utilization may have
been observed due to a multitude of reasons. First, the selection criteria of NOWS group
in our study was significantly different compared to Patrick et al. study. Our study applied
additional exclusion criteria to the NOWS group, such as LOS less than three days or more
than 60 days. Patrick et al. had reported that NOWS infants with LOS less than seven days
had comparatively higher rates of rehospitalization than those who had longer hospital
stays (up to 28 days). Our study excluded those who did not have hospital stays of more
than or equal to three days, which may have led to the differences between the two studies.
Second, the differences in effect size may also stem from where the infants may seek care
for health related problems. Since the information for any utilization is only captured when
the infant visits a center that specifically uses the CERNER EHR system, information about
all post-discharge visits may not be available. Assuming that the choice of accessing a
health center for emergency visit is random across the study groups (i.e. the probability of
choosing a health center that utilizes CERNER EHR is the same for NOWS group and
uncomplicated birth group), the effect size will be biased towards the null. Therefore, we
can speculate that the association between NOWS and emergency department visits has
been underestimated.
In comparison to mostly “unplanned” visits, such as emergency department visits
or rehospitalizations, the proportion of infants who had outpatient visits was similar in the
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NOWS group compared to the uncomplicated birth group. In the adjusted model, there was
no significant association between outpatient visit and diagnosis of NOWS. Additionally,
the absolute prevalence of any outpatient visit in NOWS group was lower than the
uncomplicated birth group. Liu et al. reported adjusted mean ratio of 1.1 (95% C.I.: 1.11.2) claims for outpatient claims in infants diagnosed with NOWS.117 It should be noted
that the Liu et al. study was based on the analysis of commercial claims data. Since
approximately 80% of the initial NOWS related birth costs are covered by Medicaid,
population-based study of infants who had commercial insurance could contribute to these
differences in findings. Furthermore, there is evidence of lower rates of child health
services use in infants born to mothers with substance use disorder.86 It is likely that in the
NOWS group, the higher number of emergency department visits and rehospitalization,
could be due to lack of or insufficiently planned routine health-care visits (e.g.: outpatient
visits and well-baby visits). Other possible reasons could be constraints on access to care
such as distance, availability of appointments.
A multitude of factors can affect emergency department or rehospitalization visits
after discharge in the first year of the infant’s life. 41,118-122 These factors range from initial
length of hospital stay following birth, the type of insurance used, the infant’s sex, and
socioeconomic factors. In addition, the presence of certain medical conditions at birth, such
as preterm birth, feeding difficulties, jaundice, convulsions, sepsis and respiratory
problems, are also known to increase the risk of emergency department visits and
readmissions to a health care facility. These factors were adjusted in the multivariable
models in our study. Factors relating to the infants family such as maternal health, socioeconomic status, nutrition, and social support mechanism are also factors that could
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potentially affect the health of an infant. The lack of these information in our study warrants
additional research.
In sub-group analysis, there were minor differences between the NOWS group and
the late preterm group regarding health care utilization. The NOWS group had marginally
lower hospital readmissions (adjusted OR: 0.8, 95% C.I.: 0.6-0.98) and any composite
visits (adjusted OR: 0.8, 95% C.I.: 0.6-0.98). Furthermore, we examined the effect of
difference in inclusion criteria across NOWS and late preterm group. After excluding
infants with LOS less than 3 days from the late preterm, group we observed some changes
in the differences in the estimates of effect size. However, the direction of association
remained the same.
The evidence suggests that during the one-year follow-up period, the NOWS and
late preterm group had similar profiles regarding health care utilization. While the etiology
and management protocols for these two groups varies, these groups face similar medical
problems during their initial stay in the hospital. Thus, inclusion of late preterm birth as a
control group in this study is justified. The evidence suggests that regardless of the
etiology, early life medical conditions potentially lead to higher levels of health care
utilization in the formative years of an infant’s life.
5.2: Discussion for Specific Aim 2
There is limited evidence regarding the impact of NOWS severity on long-term
health care utilization. The severity of NOWS was determined by several factors, including
the need for pharmacological management of NOWS, length of hospital stay following
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birth, need for the administration of second line agents (e.g.: phenobarbital), and additional
medical conditions.
Approximately 35% of the infants received pharmacological treatment for NOWS.
In our study, this was defined as receiving any methadone, morphine, tincture of opium, or
phenobarbital. Previous studies have reported a wide variation regarding the need for
pharmacological treatment for infant’s with NOWS. Research indicates this number ranges
from 15% to 90%.37,115,123 Varying definitions of what constitutes “pharmacological
management of NOWS,” (e.g.: if phenobarbital or clonidine were considered
pharmacological treatment) could be a possible reason for this variation. While minor
differences in demographic variables were observed in the Treated-For-NOWS and NotTreated-For-NOWS groups, there were significant differences in the NOWS severity
measures between the two groups. Those infants who received pharmacologic treatment
for NOWS had longer LOS and higher costs related to their initial hospital stay than those
who did not. Additionally, a higher proportion of those who received pharmacologic
treatment had respiratory problems, convulsions, feeding difficulties, and sepsis, thereby
requiring more treatment during their initial stay.
A significantly higher proportion of infants in the Treated-For-NOWS group had
emergency department visits within 30-days of discharge (10% vs. 6.2%, p<0.001) as well
as any composite visits (13% vs. 9%, p <0.001), compared to those in the Not-Treated-ForNOWS group. Higher number of emergency department visits could have potentially
driven this difference. These differences were not sustained in the adjusted model, which
suggests that these associations were confounded by other factors.
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LOS, administration of other adjunctive therapies, and the presence of medical
conditions (respiratory problems, feeding difficulties) were considered as severity
measures of NOWS. These severity measures could potentially affect post-discharge
healthcare utilization in infants with NOWS. This assessment was based on the hypothesis
that severity of NOWS could translate to higher health care utilization later in life. Previous
research has shown that the LOS at time of birth, has a non-linear effect on post-discharge
hospitalization in infants with NOWS.36 Similarly, other studies examining this impact for
those born prematurely, reported the potential of unmeasured confounding in the use of
LOS as a predictor for rehospitalization and had utilized time of birth as an instrumental
variable to predict a 7-day readmission.124 In our study, we explored various designs to
explore the effects of LOS on hospital post-discharge healthcare utilization. Linear model
as described in the results section did not show a significant effect on post-discharge health
care utilization based on LOS at birth. Next, we explored the quadratic form, equally
spaced quantiles, and the cubic splines to examine LOS in the hospital at birth as a predictor
for post-discharge health care utilization. These forms generally showed a non-linear
effect, with increasing probability of rehospitalization observed until the LOS was 20 days.
This could have been due to the fact that very short LOS could lead to poor management
of NOWS. Average LOS of around 15-20 days could mean that proper care was provided
to the infants thereby lowering the chances of post-discharge health care utilization.
Considerable variability in the risk of post-discharge health care utilization was observed
across the models when LOS exceeded 20 days. Longer lengths of stay (greater than 20
days) could mean that there were other medical conditions or that the NOWS symptoms
were very severe. This could potentially lead to higher post-discharge health care
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utilization after the discharge. These findings are fairly consistent with the estimates
reported by Patrick et al.36 Additional information regarding the medications and medical
conditions diagnosed during the initial stay following birth were available in our study.
These factors could be adjusted in full models, however, we chose to use the linear form
of the variables in our statistical models.
We also examined additional diagnostic codes received by those in the NOWS
group and found that there was a consistent effect on post-discharge healthcare utilization
regarding the presence or absence of respiratory problems in the NOWS group. It is likely
that infants in the NOWS group with respiratory problems, require further management
and health care services after their discharge for this medical condition. Feeding
difficulties, jaundice, and sepsis showed a minor impact on post-discharge healthcare
utilization. The medical conditions we used as factors potentially leading to readmission in
the hospital have been shown by studies to be common causes for readmission in the
hospital following birth for the general population. It is likely that the presence of
diagnostic codes for these conditions, resulted in the proper management of these
conditions, and minimized their long-term effects. In our study, we only included infants
with NOWS who remained in the hospital for at least three days following birth. That
criterion allowed sufficient time of observation in order to diagnose, or rule out, medical
conditions that could lead to higher rates of early rehospitalization or emergency
department visits.
Overall, analysis of factors relating to NOWS severity showed limited association
with post-discharge healthcare utilization during a follow-up period of one-year. This
finding may have been observed due to multiple reasons. First, the presence of the
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diagnostic codes for medical conditions, or pharmaceutical treatment, could imply that the
condition was managed efficiently during the initial hospital stay. Thus, the likelihood of
early health care utilization, either through an emergency department visit within 30 days
or rehospitalization within 30 days, would be limited to extraneous conditions that would
not be specific to NOWS. Furthermore, while the NOWS group had higher health care
utilization overall, it is possible this is due to other conditions not directly related with
NOWS. Examination of reasons for follow up health care encounters in infants with
NOWS after the age of 15 days (average LOS for infants with NOWS) were revealed that
conditions, such as acute upper respiratory tract infection, bronchitis, and cough, were
common in the post-discharge visits. However, there was an association between the
composite measure of NOWS severity (first principal component) and post-discharge
health care utilization. As principal component analysis reduces the different measures of
NOWS severity into uncorrelated composite measures, these composite measures can
serve as better predictors in the regression models.
It is to be noted that across all the analysis, there were significant effect of infant
sex and insurance status on post-discharge healthcare utilization. Male infants had
significantly higher rates of hospitalization but not emergency department visits. In
addition, infants whose initial visits were covered through Medicaid had higher health care
utilization. The increased utilization could be due to comparatively lower out-of-pocket
costs. It could also be considered a marker for poor socioeconomic condition, which could
lead to poor health of the infant, thereby increasing the risk of post-discharge health care
utilization.
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5.3: Limitations of the study
Our study has several limitations. The primary limitation is the reliance on hospital
administrative databases for the diagnosis of a medical conditions.125-127 Diagnostic codes
are used for administrative/reimbursement purposes, and are not primarily intended for
research purposes. However, the wealth of data collected during patients’ encounters with
a health care system, combined with the sheer volume of the data generated in the process,
make these administrative databases a “gold-mine” for researchers. The findings, however,
should be interpreted with an awareness of the limitations of these databases.
As with any retrospective data analysis, the findings of this study rely on the
accuracy of the databases. Infants who show symptoms of withdrawal syndrome are
assigned the ICD-9-CM code 779.5 (ICD-10-CM: P96.1). ICD-9-CM code 779.5 refers to
“Drug withdrawal syndrome in newborn” and ICD-10-CM code refers to “Neonatal
withdrawal symptoms from maternal use of drugs of addiction”. These codes are not
specific to just opioid exposure. Thus, there is a likelihood of potential misclassification
regardless of the exposure; it is possible that infants who were not exposed to prenatal
opioids, were included in the study as those who were exposed, and led to an erroneous
estimate of the effect size. It is important to note that withdrawal syndrome is primarily
attributed to opioids due to the high prevalence of opioid use in the United States. Previous
studies have noted that the use of the diagnostic codes for identification of infants with
NOWS, has a high positive predictive value (91% for ICD-9-CM code and 98.2% for ICD10-CM)93. Furthermore, the use of LOS in the hospital following birth as an additional
criterion leads to increased accuracy in diagnosing NOWS.
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Second, this study is based on the analysis of clinical data, therefore detailed
information on maternal health, socioeconomic status, marital status, maternal education,
breastfeeding, and substance abuse is lacking. Type and intensity of maternal opioid
exposure could be significant in predicting long-term health care utilization in infants with
NOWS. There is no direct link between mother and infant records within the HF database,
thus making this type of analysis difficult. Poor maternal health, social, and economic
problems can lead to adverse health outcomes in infants, which could lead to increased
health-care utilization in terms of emergency visits and rehospitalizations. Additionally,
the same factors could impact the general care of the infant. For example, a missed general
health-care appointment because of poor care or resources could cause greater health care
utilization in term of emergency department visits and rehospitalization in the long run. A
majority of infants born with a diagnosis of NOWS, have mothers who are either active
substance users or managed on a maintenance therapy. In general, risk factors such as poor
social support network, stigma for the society, lack of economic means, unstable housing,
abuse, poor nutrition, behavioral health disorders, anxiety, depression, alcohol use, and
infectious diseases (HIV/HCV) are prevalent in these populations.8,128-131 These factors, in
combination with limited resources for the care of the infant, may lead to poor health, and
increase the chances of health care utilization which could have been potentially avoided.
Third, there are limitations to the estimates of the amount of treatment received by
the infant during their hospital stay for NOWS. Initially, we sought to quantify the amount
of opioids the infant received for management of withdrawal symptoms during their initial
hospital stay. There were limitations in the database regarding quantification of
medications, such as oral morphine for the management of NOWS, as the solution has to
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be diluted several times (up to 0.04 mg/ml from original concentration of 10mg/5ml or
5mg/5ml) before administration. While the information on the strength and timing of
administration of morphine and methadone was available, there was no reliable
information on dilution or the strength of the medication administered to the infants.
Furthermore, there is no consensus on conversion of methadone to morphine equivalents,
specifically in relation to management of NOWS. Conversion factors range from 1:3 to 1:4
for lower doses, but the variability in conversion increases as the dose increases.132
Fourth, a simple Poisson model does not account for the dependency of outcomes.
For example, infants who had an emergency department visit are more likely to have
subsequent department visits because of their medical condition. The assumption of
independence in Poisson models is violated by these recurrent events. Additionally, when
examining all three groups (NOWS, late preterm births, and uncomplicated births), a
majority of the infants in the study had no emergency visits or rehospitalizations within 30days of discharge. This leads to a high number of zero values in the outcome variable. We
addressed this problem by the utilization of Zero-inflated Poisson as a robust alternative to
Poisson regression.
Fifth, errors relating to censoring of data because they accessed care in different
health care centers whereby their information was not captured in the Cerner HealthFacts
database could bias the results in our study. It is likely that a fraction of a sample across all
the study groups who required service from a healthcare center whether it may be
emergency department visits or hospital readmission may seek care in institutions that do
not use the CERNER EHR system. While there is a probability that this absence could lead
to underestimation of the actual number of visits, the effect on the odds ratio of these events
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in NOWS group compared to controls would be minimal. This is based on the assumption
that infants would seek care from healthcare institutions irrespective of the EHR being
utilized at that institution.
Based on the results of our study and previous studies, let us assume that the rate
of rehospitalization across during the follow up period in the NOWS group and the
uncomplicated birth group is 4% and 2%, respectively. Based on this hypothetical data, the
OR would be 2.04. Assuming that only 75% of these visits are captured in CERNER
system, the observed OR would be 2.03. Even at a rate of 25% of these events occurring
in a health care system that uses CERNER EHR, the observed OR would approximate 2.01.
While the estimates of post-discharge health care observed in our study were lower than
observed elsewhere, they were proportionately similar across the study groups. Given that
the probability of seeking care at any given hospital is random across study groups, the
observed effect size is very robust.
Finally, generalizability of the study might be limited. However, our dataset spans
hospitals and health care centers across the United States, and covers a wide range of
demographics. Previous studies were either limited geographically,

35,36,116

or, did not

include a majority of the infants who present with NOWS117. HF database covers over 500
health centers across the United States, thus, increasing our study’s generalizability
compared to previous studies.
Even in the light of the above limitations, we believe that our study contributes to
the existing literature relating to long-term health care utilization in infants with NOWS.
By using a measure of the severity of NOWS as a predictor of future health care utilization,
we have added another dimension to the study of effects of opioid withdrawal. We believe
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that the findings of this study can lead to the formulation of policy that will ensure proper
follow-up and evaluation of these infants. In this era of the opioid use epidemic in the
United States, we believe that this study can contribute to the overall understanding of the
long-term effects of prenatal opioid exposure.
5.4: Implications of the study
As the opioid crisis expands long-term effects of NOWS warrant greater attention.
There are conflicting reports of the long-term impact of NOWS. Recent studies on infants
born to women who were on MAT showed no difference in development in their early
childhood compared to infants who were not exposed to prenatal opioids.84,85 Existing
literature also suggests a variety of risks for infants with NOWS such as cognitive,
behavioral deficits at young age, and poor school performance when these infants reach
older age.83 There is limited data on post-discharge health care service utilization in infants
who were diagnosed with NOWS.36,117 Our study shows consistent evidence of increased
rehospitalization in infants with NOWS compared to uncomplicated birth infants in the
one-year follow-up period after discharge. However, impact of NOWS on emergency
department visits, and outpatient visits, is still inconsistent across studies.
The results from our study showed that the rates of post-discharge health care
utilization were not specific to the severity of NOWS. While certain diagnoses at birth were
related to increased post-discharge health care utilization the association was not
consistent. The principal component analysis in our study where the severity of NOWS
was transformed into uncorrelated components showed consistent association with postdischarge health care utilization. Hence, a scaled measure of NOWS severity could be vital
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in predicting post-discharge health care utilization. Maternal substance use, poor nutrition,
lack of social support, and poor pre/postnatal care may also lead to higher health care needs
for these infants. Numerous studies have shown the impact of environment and family on
the health of an infant.133 Women with substance use disorders have high rates of mental
health disorders and unemployment, and are more likely to have a history of abuse, poor
nutrition, and limited social support.8,86,128,129 These forces, in combination with the effects
of opioid exposure and subsequent withdrawal effects, may contribute to higher health care
needs and thus, health care utilization for these infants.
Hospital readmission and emergency department visits are costly to tax-payers,
disruptive to patients and their families, and may increase stress and financial hardships for
patients and families as well. Closer follow-up and management of infants with NOWS is
needed to minimize emergency department visits and unplanned rehospitalization.
Providing additional resources and a comprehensive care environment could lead to
improved health outcomes in infants with NOWS. It is recommended that these infants
have regular well-child visits for evaluation of any signs of medical condition that could
warrant proper medical care.
5.5: Future research
Our study shows that infants with NOWS have a higher risk of post-discharge
health care utilization compared to controls. Based on this piece of evidence, a two-pronged
approach to future research is suggested. First, research should be focused towards
reducing “preventable and unplanned” health-care utilization events and improving regular
check-up/follow-up visits in infants who are either diagnosed with NOWS or experienced
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in-utero exposure to opioids. Research aimed at improving the mental and physical needs
of the mother is also recommended, as improvement in her health may translate to
improvement in the infant’s health. Providing improved social support, ensuring ease of
access to health services, such as treatment for OUD, counseling, proper nutrition, and
arrangement for proper housing, may lead to increased stability in the surrounding
environment of the infant. Studies focusing on implementation of these interventions and
their effectiveness on improving the infant health outcomes are necessary.
Second, future research could benefit by addressing the limitations of our study.
We were not able to link maternal health information to infant data. Maternal health
information could be key in further explaining post-discharge health care utilization.
Furthermore, a greater focus on the future impact of the exposure to opioids within the
context of NOWS management, is merited. Our study could not explore dose-response
relationship of opioids in relation to post-discharge healthcare utilization. Detailed
examination of these treatments could reveal unexplained variations in the outcomes of our
study (or infants born with NOWS).
Our study did not specifically evaluate the reasons for post-discharge healthcare
utilization. Little is known about the reasons what specific events or conditions results in
emergency visits or rehospitalization. Examining the causes of these health care utilization
events could help guide policy in creating policies to minimize unnecessary hospital
readmissions and/or emergency room visits. There would also be additional benefit of
following up these infants for a longer period of time to examine their health outcomes in
adulthood. Other avenues of research include study of long-term economic impact of
increased post-discharge health care utilization. Additionally, cost-effectiveness analysis
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of difference measures of NOWS management (e.g. ESC or institution specific methods of
care) would help facilitate adoption of these measures.
Understanding how NOWS affects an infant holds the key to promoting policies
and interventions that can improve health outcomes. We believe that this study provides a
greater understanding of the long-term effects of NOWS. We hope this study serves as a
guide for future research in improving the lives of infants diagnosed with NOWS at birth.
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